WO2004014893A2 - Antimicrobial aza-bicyclic derivates, their compositions and uses - Google Patents
Antimicrobial aza-bicyclic derivates, their compositions and uses Download PDFInfo
- Publication number
- WO2004014893A2 WO2004014893A2 PCT/US2003/022587 US0322587W WO2004014893A2 WO 2004014893 A2 WO2004014893 A2 WO 2004014893A2 US 0322587 W US0322587 W US 0322587W WO 2004014893 A2 WO2004014893 A2 WO 2004014893A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- amino
- fluoro
- cyclopropyl
- oxo
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title description 174
- 230000000845 anti-microbial effect Effects 0.000 title description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 128
- 125000000217 alkyl group Chemical group 0.000 claims description 119
- 239000001257 hydrogen Substances 0.000 claims description 86
- 229910052739 hydrogen Inorganic materials 0.000 claims description 86
- 150000001336 alkenes Chemical class 0.000 claims description 78
- -1 hydroxy, amino Chemical group 0.000 claims description 77
- 125000003545 alkoxy group Chemical group 0.000 claims description 76
- 150000001345 alkine derivatives Chemical class 0.000 claims description 66
- 125000001153 fluoro group Chemical group F* 0.000 claims description 59
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 52
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 44
- 125000003118 aryl group Chemical group 0.000 claims description 38
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 36
- 150000002431 hydrogen Chemical group 0.000 claims description 36
- 125000004432 carbon atom Chemical group C* 0.000 claims description 34
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 31
- 229910052799 carbon Inorganic materials 0.000 claims description 30
- 125000001072 heteroaryl group Chemical group 0.000 claims description 27
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 27
- 208000015181 infectious disease Diseases 0.000 claims description 25
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 23
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- 125000003342 alkenyl group Chemical group 0.000 claims description 16
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 16
- 125000000304 alkynyl group Chemical group 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 125000004414 alkyl thio group Chemical group 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 230000003287 optical effect Effects 0.000 claims description 11
- 150000001408 amides Chemical class 0.000 claims description 10
- 125000001246 bromo group Chemical group Br* 0.000 claims description 10
- 125000003386 piperidinyl group Chemical group 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 150000003949 imides Chemical class 0.000 claims description 9
- 125000002950 monocyclic group Chemical group 0.000 claims description 9
- 230000000813 microbial effect Effects 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000004001 thioalkyl group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- QVJANVVXBWNOSF-UHFFFAOYSA-N 3-amino-7-(7-amino-5-azaspiro[2.5]octan-2-yl)-1-cyclopropyl-6-fluoro-8-methylquinazoline-2,4-dione Chemical compound FC1=CC(C(N(N)C(=O)N2C3CC3)=O)=C2C(C)=C1C1CC11CNCC(N)C1 QVJANVVXBWNOSF-UHFFFAOYSA-N 0.000 claims 1
- KJJRIDZYTKSRHW-UHFFFAOYSA-N 3-amino-7-(8-amino-6-azaspiro[3.5]nonan-3-yl)-1-cyclopropyl-6-fluoro-8-methylquinazoline-2,4-dione Chemical compound FC1=CC(C(N(N)C(=O)N2C3CC3)=O)=C2C(C)=C1C1CCC11CNCC(N)C1 KJJRIDZYTKSRHW-UHFFFAOYSA-N 0.000 claims 1
- QCPHOKICUIMOCL-UHFFFAOYSA-N 8-(7-amino-5-azaspiro[2.5]octan-2-yl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxoquinolizine-3-carboxylic acid Chemical compound FC1=CN(C(C(C(O)=O)=CC=2C3CC3)=O)C=2C(C)=C1C1CC11CNCC(N)C1 QCPHOKICUIMOCL-UHFFFAOYSA-N 0.000 claims 1
- ULYRRLMWEQVNDT-UHFFFAOYSA-N 8-(8-amino-6-azaspiro[3.5]nonan-3-yl)-1-cyclopropyl-7-fluoro-9-methyl-4-oxoquinolizine-3-carboxylic acid Chemical compound FC1=CN(C(C(C(O)=O)=CC=2C3CC3)=O)C=2C(C)=C1C1CCC11CNCC(N)C1 ULYRRLMWEQVNDT-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 abstract description 12
- 239000000243 solution Substances 0.000 description 192
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 161
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 123
- 239000000047 product Substances 0.000 description 114
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 105
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 103
- 239000002243 precursor Substances 0.000 description 94
- 229910001868 water Inorganic materials 0.000 description 87
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 77
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 68
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 66
- 238000003818 flash chromatography Methods 0.000 description 66
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 60
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 60
- 239000002904 solvent Substances 0.000 description 56
- 235000019439 ethyl acetate Nutrition 0.000 description 55
- 239000011541 reaction mixture Substances 0.000 description 54
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 52
- 238000000034 method Methods 0.000 description 52
- 239000000741 silica gel Substances 0.000 description 50
- 229910002027 silica gel Inorganic materials 0.000 description 50
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 47
- 238000001914 filtration Methods 0.000 description 43
- 239000012044 organic layer Substances 0.000 description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 239000012267 brine Substances 0.000 description 37
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 37
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 34
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- 238000010992 reflux Methods 0.000 description 32
- 239000010410 layer Substances 0.000 description 31
- 238000003756 stirring Methods 0.000 description 31
- 229910052786 argon Inorganic materials 0.000 description 30
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 29
- 229920006395 saturated elastomer Polymers 0.000 description 28
- 239000003921 oil Substances 0.000 description 27
- 235000019198 oils Nutrition 0.000 description 27
- 239000007787 solid Substances 0.000 description 26
- 230000002829 reductive effect Effects 0.000 description 24
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 23
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 21
- 238000007792 addition Methods 0.000 description 20
- 239000000284 extract Substances 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- 239000011734 sodium Substances 0.000 description 19
- 238000001704 evaporation Methods 0.000 description 18
- 230000008020 evaporation Effects 0.000 description 18
- 239000007858 starting material Substances 0.000 description 18
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 15
- 230000000844 anti-bacterial effect Effects 0.000 description 15
- 238000001816 cooling Methods 0.000 description 14
- 239000000376 reactant Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 13
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 13
- 125000004429 atom Chemical group 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 125000005842 heteroatom Chemical group 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- 239000003039 volatile agent Substances 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 125000001188 haloalkyl group Chemical group 0.000 description 11
- 230000000670 limiting effect Effects 0.000 description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 150000001721 carbon Chemical group 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 10
- 239000012043 crude product Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- 0 COc(c(F)c(cc1*)F)c1F Chemical compound COc(c(F)c(cc1*)F)c1F 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 125000004104 aryloxy group Chemical group 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 150000007660 quinolones Chemical class 0.000 description 8
- 239000002002 slurry Substances 0.000 description 8
- FAUQRRGKJKMEIW-UHFFFAOYSA-N 2-cyclopropylacetonitrile Chemical compound N#CCC1CC1 FAUQRRGKJKMEIW-UHFFFAOYSA-N 0.000 description 7
- 125000004442 acylamino group Chemical group 0.000 description 7
- 125000003368 amide group Chemical group 0.000 description 7
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 7
- 125000005553 heteroaryloxy group Chemical group 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229940098779 methanesulfonic acid Drugs 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- 125000001183 hydrocarbyl group Chemical group 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000007911 parenteral administration Methods 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- CNALVHVMBXLLIY-IUCAKERBSA-N tert-butyl n-[(3s,5s)-5-methylpiperidin-3-yl]carbamate Chemical compound C[C@@H]1CNC[C@@H](NC(=O)OC(C)(C)C)C1 CNALVHVMBXLLIY-IUCAKERBSA-N 0.000 description 6
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 4
- 229930194542 Keto Natural products 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 231100000010 clastogenicity Toxicity 0.000 description 4
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 125000000468 ketone group Chemical group 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 4
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 3
- LFIVFMAMROTIED-UHFFFAOYSA-N 3-amino-1-cyclopropyl-6,7-difluoro-8-methylquinazoline-2,4-dione Chemical compound CC1=C(F)C(F)=CC(C(N(N)C2=O)=O)=C1N2C1CC1 LFIVFMAMROTIED-UHFFFAOYSA-N 0.000 description 3
- YGYZTZAEZMCPSC-UHFFFAOYSA-N 3-chloro-2,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(Cl)=C1F YGYZTZAEZMCPSC-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 229910007928 ZrCl2 Inorganic materials 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229960003405 ciprofloxacin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229940045803 cuprous chloride Drugs 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000004663 dialkyl amino group Chemical group 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229940100684 pentylamine Drugs 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 3
- SAMHKCXIYKSVRF-UWVGGRQHSA-N tert-butyl n-[(3s,5s)-5-ethylpiperidin-3-yl]carbamate Chemical compound CC[C@@H]1CNC[C@@H](NC(=O)OC(C)(C)C)C1 SAMHKCXIYKSVRF-UWVGGRQHSA-N 0.000 description 3
- 125000005323 thioketone group Chemical group 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- LOZWAPSEEHRYPG-UHFFFAOYSA-N 1,4-dithiane Chemical compound C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 2
- VOXXHAPAYAVTJD-UHFFFAOYSA-N 2,3,6-trifluoro-4-[(2-methylpropan-2-yl)oxy]pyridine Chemical compound CC(C)(C)OC1=CC(F)=NC(F)=C1F VOXXHAPAYAVTJD-UHFFFAOYSA-N 0.000 description 2
- JVQSZTJTWSUJCR-UHFFFAOYSA-N 2,4,5-trifluoro-3-methoxybenzoyl chloride Chemical compound COC1=C(F)C(F)=CC(C(Cl)=O)=C1F JVQSZTJTWSUJCR-UHFFFAOYSA-N 0.000 description 2
- WLKJUQJFLRTPKL-UHFFFAOYSA-N 2-[2-(4-chloro-3-methyl-5-nitropyridin-2-yl)cyclopropyl]acetonitrile Chemical compound CC1=C(Cl)C([N+]([O-])=O)=CN=C1C1C(CC#N)C1 WLKJUQJFLRTPKL-UHFFFAOYSA-N 0.000 description 2
- IFZDYNYZWOBYIG-UHFFFAOYSA-N 2-amino-3-chloro-4,5-difluorobenzoic acid Chemical compound NC1=C(Cl)C(F)=C(F)C=C1C(O)=O IFZDYNYZWOBYIG-UHFFFAOYSA-N 0.000 description 2
- DUKAXINRLMKHHN-UHFFFAOYSA-N 2-bromo-3-chloro-4,5-difluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=C(F)C(Cl)=C1Br DUKAXINRLMKHHN-UHFFFAOYSA-N 0.000 description 2
- VXDHQYLFEYUMFY-UHFFFAOYSA-N 2-methylprop-2-en-1-amine Chemical compound CC(=C)CN VXDHQYLFEYUMFY-UHFFFAOYSA-N 0.000 description 2
- PUTHSDYYDURNPS-UHFFFAOYSA-N 3-chloro-2,4-difluoro-5-nitrobenzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=C(F)C(Cl)=C1F PUTHSDYYDURNPS-UHFFFAOYSA-N 0.000 description 2
- IJXIUTUHWPSBGU-UHFFFAOYSA-N 3-chloro-2,4-difluoro-5-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC(C(Cl)=O)=C(F)C(Cl)=C1F IJXIUTUHWPSBGU-UHFFFAOYSA-N 0.000 description 2
- NSFFUUCTCIWHRO-UHFFFAOYSA-N 3-chloro-2-(cyclopropylamino)-4,5-difluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=C(F)C(Cl)=C1NC1CC1 NSFFUUCTCIWHRO-UHFFFAOYSA-N 0.000 description 2
- HGINADPHJQTSKN-UHFFFAOYSA-M 3-ethoxy-3-oxopropanoate Chemical compound CCOC(=O)CC([O-])=O HGINADPHJQTSKN-UHFFFAOYSA-M 0.000 description 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- HCKHDPKRFFTFLB-UHFFFAOYSA-N 5-bromo-3-chloro-2,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC(Br)=C(F)C(Cl)=C1F HCKHDPKRFFTFLB-UHFFFAOYSA-N 0.000 description 2
- SWAIGMMHZYAIRQ-UHFFFAOYSA-N 5-bromo-3-chloro-2,4-difluorobenzoyl chloride Chemical compound FC1=C(Br)C=C(C(Cl)=O)C(F)=C1Cl SWAIGMMHZYAIRQ-UHFFFAOYSA-N 0.000 description 2
- SDKZYZHBZWXQAZ-UHFFFAOYSA-N 6-bromo-1-chloro-2,6-difluorocyclohexa-1,3-diene Chemical compound ClC=1C(CC=CC=1F)(Br)F SDKZYZHBZWXQAZ-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 229930186147 Cephalosporin Natural products 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101100295738 Gallus gallus COR3 gene Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- HGINADPHJQTSKN-UHFFFAOYSA-N Monoethyl malonic acid Chemical compound CCOC(=O)CC(O)=O HGINADPHJQTSKN-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 108700020474 Penicillin-Binding Proteins Proteins 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- FUJURQDZVCERHZ-UHFFFAOYSA-N S=C(OC1=CC=CC=C1)[S+]=NC1CC1 Chemical compound S=C(OC1=CC=CC=C1)[S+]=NC1CC1 FUJURQDZVCERHZ-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- QSLPQKTWXSBTFM-UHFFFAOYSA-N [B](F)F.ClC=1C(=C(C=C2C(C(=CN(C12)C1CC1)C(=O)O)=O)C)F Chemical compound [B](F)F.ClC=1C(=C(C=C2C(C(=CN(C12)C1CC1)C(=O)O)=O)C)F QSLPQKTWXSBTFM-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 150000001780 cephalosporins Chemical class 0.000 description 2
- KWTSZCJMWHGPOS-UHFFFAOYSA-M chloro(trimethyl)stannane Chemical compound C[Sn](C)(C)Cl KWTSZCJMWHGPOS-UHFFFAOYSA-M 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- HAECHYRFZFEOOZ-UHFFFAOYSA-N ethyl 2-[2-(4-chloro-5-fluoro-3-methylpyridin-2-yl)cyclopropyl]acetate Chemical compound CCOC(=O)CC1CC1C1=NC=C(F)C(Cl)=C1C HAECHYRFZFEOOZ-UHFFFAOYSA-N 0.000 description 2
- PFCLZHFBTQZBGS-UHFFFAOYSA-N ethyl 2-amino-4,5-difluoro-3-methylbenzoate Chemical compound CCOC(=O)C1=CC(F)=C(F)C(C)=C1N PFCLZHFBTQZBGS-UHFFFAOYSA-N 0.000 description 2
- IEUHWNLWVMLHHC-UHFFFAOYSA-N ethyl 3-(2,6-dichloro-5-fluoropyridin-3-yl)-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)C1=CC(F)=C(Cl)N=C1Cl IEUHWNLWVMLHHC-UHFFFAOYSA-N 0.000 description 2
- CWBDZGOBRZAYMQ-UHFFFAOYSA-N ethyl 4,5-difluoro-2-nitrobenzoate Chemical compound CCOC(=O)C1=CC(F)=C(F)C=C1[N+]([O-])=O CWBDZGOBRZAYMQ-UHFFFAOYSA-N 0.000 description 2
- CZWOEPIYDWRSSK-UHFFFAOYSA-N ethyl 8-chloro-1-cyclopropyl-7-fluoro-9-methyl-4-oxoquinolizine-3-carboxylate Chemical compound C=12C(C)=C(Cl)C(F)=CN2C(=O)C(C(=O)OCC)=CC=1C1CC1 CZWOEPIYDWRSSK-UHFFFAOYSA-N 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229940124307 fluoroquinolone Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- DPBLXKKOBLCELK-UHFFFAOYSA-N n-pentylamine Natural products CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- KTUXZCJQJNQPPH-UHFFFAOYSA-N quinoline-3,4-dione Chemical compound C1=CC=C2C(=O)C(=O)C=NC2=C1 KTUXZCJQJNQPPH-UHFFFAOYSA-N 0.000 description 2
- 229940072132 quinolone antibacterials Drugs 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000001476 sodium potassium tartrate Substances 0.000 description 2
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 2
- 229910001495 sodium tetrafluoroborate Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- QUTRKKUYVZIMQK-VIFPVBQESA-N tert-butyl n-[(3s)-5,5-dimethylpiperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CNCC(C)(C)C1 QUTRKKUYVZIMQK-VIFPVBQESA-N 0.000 description 2
- YBLVNGFGZYQUHA-RGURZIINSA-N tert-butyl n-[(8r)-8-methyl-5-azaspiro[2.5]octan-7-yl]carbamate Chemical compound C[C@H]1C(NC(=O)OC(C)(C)C)CNCC11CC1 YBLVNGFGZYQUHA-RGURZIINSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- BZMMRNKDONDVIB-UHFFFAOYSA-N (1-ethoxycyclopropyl)oxy-trimethylsilane Chemical compound CCOC1(O[Si](C)(C)C)CC1 BZMMRNKDONDVIB-UHFFFAOYSA-N 0.000 description 1
- GUEYIHNUYMVLQV-CYBMUJFWSA-N (2R)-1-benzyl-2,5,5-trimethylpiperidine Chemical compound C[C@H]1N(CC(CC1)(C)C)CC1=CC=CC=C1 GUEYIHNUYMVLQV-CYBMUJFWSA-N 0.000 description 1
- 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- PGXYPPULOOXZCY-UHFFFAOYSA-N 1,2,4-oxadiazole;1,3,4-oxadiazole;oxatriazole;thiatriazole;1,2,3,5-thiatriazole Chemical compound C=1N=CON=1.C=1N=NSN=1.C1=NN=CO1.C1=NN=NO1.C1=NN=NS1 PGXYPPULOOXZCY-UHFFFAOYSA-N 0.000 description 1
- AMGGSWGYRYIGRF-UHFFFAOYSA-N 1,2,5-oxadiazole 1,2,5-thiadiazole 1,3,4-thiadiazole 1,2-thiazole 1,3-thiazole 2H-triazole Chemical compound O1N=CC=N1.S1C=NN=C1.N1N=NC=C1.S1N=CC=N1.S1C=NC=C1.S1N=CC=C1 AMGGSWGYRYIGRF-UHFFFAOYSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
- VJXJUOLMRDTWMX-UHFFFAOYSA-N 1,3-dioxane;oxane Chemical compound C1CCOCC1.C1COCOC1 VJXJUOLMRDTWMX-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-UCVXFZOQSA-N 1-[(2s,3s,4s,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@H]1[C@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UCVXFZOQSA-N 0.000 description 1
- VJUFSRBHFOGFNY-UHFFFAOYSA-N 1-benzofuran 1-benzothiophene 2H-isoindole Chemical compound S1C=CC2=C1C=CC=C2.O2C=CC1=C2C=CC=C1.C=1NC=C2C=CC=CC12 VJUFSRBHFOGFNY-UHFFFAOYSA-N 0.000 description 1
- MGHBDQZXPCTTIH-UHFFFAOYSA-N 1-bromo-2,4-difluorobenzene Chemical compound FC1=CC=C(Br)C(F)=C1 MGHBDQZXPCTTIH-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- ZFRUGZMCGCYBRC-UHFFFAOYSA-N 1h-1,8-naphthyridin-2-one Chemical compound C1=CC=NC2=NC(O)=CC=C21 ZFRUGZMCGCYBRC-UHFFFAOYSA-N 0.000 description 1
- XWCKIXLTBNGIHV-UHFFFAOYSA-N 2,3,4,5-tetrafluorobenzoyl chloride Chemical compound FC1=CC(C(Cl)=O)=C(F)C(F)=C1F XWCKIXLTBNGIHV-UHFFFAOYSA-N 0.000 description 1
- GGDAMLYJTPTHPO-UHFFFAOYSA-N 2,3,6-trifluoro-5-methyl-4-[(2-methylpropan-2-yl)oxy]pyridine Chemical compound CC1=C(F)N=C(F)C(F)=C1OC(C)(C)C GGDAMLYJTPTHPO-UHFFFAOYSA-N 0.000 description 1
- MWMMJUHXDRVMJO-UHFFFAOYSA-N 2,4,6-trifluoro-3-nitropyridine Chemical compound [O-][N+](=O)C1=C(F)C=C(F)N=C1F MWMMJUHXDRVMJO-UHFFFAOYSA-N 0.000 description 1
- UZDRWXKBKVVUTE-UHFFFAOYSA-N 2,4,6-trifluoropyridine Chemical compound FC1=CC(F)=NC(F)=C1 UZDRWXKBKVVUTE-UHFFFAOYSA-N 0.000 description 1
- POXLAZYABVJULR-UHFFFAOYSA-N 2-[2-(3-methyl-5-nitro-4-oxo-1h-pyridin-2-yl)cyclopropyl]acetonitrile Chemical compound CC1=C(O)C([N+]([O-])=O)=CN=C1C1C(CC#N)C1 POXLAZYABVJULR-UHFFFAOYSA-N 0.000 description 1
- AUPGKIADBSAGBZ-UHFFFAOYSA-N 2-[2-(4-chloro-3-methyl-5-nitropyridin-2-yl)cyclopropyl]acetaldehyde Chemical compound CC1=C(Cl)C([N+]([O-])=O)=CN=C1C1C(CC=O)C1 AUPGKIADBSAGBZ-UHFFFAOYSA-N 0.000 description 1
- VUPQRDITKXATER-UHFFFAOYSA-N 2-[2-(4-chloro-3-methyl-5-nitropyridin-2-yl)cyclopropyl]ethanol Chemical compound CC1=C(Cl)C([N+]([O-])=O)=CN=C1C1C(CCO)C1 VUPQRDITKXATER-UHFFFAOYSA-N 0.000 description 1
- HOCPDZYITUKADN-UHFFFAOYSA-N 2-[2-(4-chloro-5-fluoro-3-methylpyridin-2-yl)cyclopropyl]acetaldehyde Chemical compound CC1=C(Cl)C(F)=CN=C1C1C(CC=O)C1 HOCPDZYITUKADN-UHFFFAOYSA-N 0.000 description 1
- JPOQEMDFWMYVSQ-UHFFFAOYSA-N 2-[2-(4-chloro-5-fluoro-3-methylpyridin-2-yl)cyclopropyl]acetonitrile Chemical compound CC1=C(Cl)C(F)=CN=C1C1C(CC#N)C1 JPOQEMDFWMYVSQ-UHFFFAOYSA-N 0.000 description 1
- UNALVTWCPWRZEQ-UHFFFAOYSA-N 2-[2-(4-chloro-5-fluoro-3-methylpyridin-2-yl)cyclopropyl]ethanol Chemical compound CC1=C(Cl)C(F)=CN=C1C1C(CCO)C1 UNALVTWCPWRZEQ-UHFFFAOYSA-N 0.000 description 1
- ZXWPJTLJHFWQRY-UHFFFAOYSA-N 2-[2-(5-fluoro-3-methyl-4-oxo-1h-pyridin-2-yl)cyclopropyl]acetonitrile Chemical compound CC1=C(O)C(F)=CN=C1C1C(CC#N)C1 ZXWPJTLJHFWQRY-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- XVLOGBLJDQMGLA-UHFFFAOYSA-N 2H-benzotriazole 2H-tetrazole thiadiazole 1,2,4-thiadiazole 1H-1,2,4-triazole Chemical compound N1N=NN=C1.N1N=CN=C1.N1N=NC2=C1C=CC=C2.S2N=CN=C2.S2N=NC=C2 XVLOGBLJDQMGLA-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- JZIBVTUXIVIFGC-UHFFFAOYSA-N 2H-pyrrole Chemical compound C1C=CC=N1 JZIBVTUXIVIFGC-UHFFFAOYSA-N 0.000 description 1
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 description 1
- PKSORSNCSXBXOT-UHFFFAOYSA-N 3,5-dichloro-2,4,6-trifluoropyridine Chemical compound FC1=NC(F)=C(Cl)C(F)=C1Cl PKSORSNCSXBXOT-UHFFFAOYSA-N 0.000 description 1
- UXUZMYHSICIOQT-UHFFFAOYSA-N 3-chloro-2,4,5,6-tetrafluoropyridine Chemical compound FC1=NC(F)=C(Cl)C(F)=C1F UXUZMYHSICIOQT-UHFFFAOYSA-N 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- ZNBUXTFASGDVCL-UHFFFAOYSA-N 3-o-tert-butyl 4-o-methyl 2,2-dimethyl-1,3-oxazolidine-3,4-dicarboxylate Chemical compound COC(=O)C1COC(C)(C)N1C(=O)OC(C)(C)C ZNBUXTFASGDVCL-UHFFFAOYSA-N 0.000 description 1
- HGGRAOYTQNFGGN-UHFFFAOYSA-N 4,5-difluoro-2-nitrobenzoic acid Chemical compound OC(=O)C1=CC(F)=C(F)C=C1[N+]([O-])=O HGGRAOYTQNFGGN-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- IQOZTIKBIHWYQQ-UHFFFAOYSA-N 4h-1,3-oxazine Chemical compound C1C=COC=N1 IQOZTIKBIHWYQQ-UHFFFAOYSA-N 0.000 description 1
- CPPUYLRKSSJSKZ-UHFFFAOYSA-N 6-amino-8-methyl-1h-quinolin-2-one Chemical class C1=CC(=O)NC2=C1C=C(N)C=C2C CPPUYLRKSSJSKZ-UHFFFAOYSA-N 0.000 description 1
- 150000005016 6-aminoquinolines Chemical class 0.000 description 1
- GMLMFZXBPRIXPK-UHFFFAOYSA-N 6h-1,3-oxazine Chemical compound C1OC=NC=C1 GMLMFZXBPRIXPK-UHFFFAOYSA-N 0.000 description 1
- XJPQCGZMDOXKRK-UHFFFAOYSA-N 7h-purine;quinoline Chemical compound C1=NC=C2NC=NC2=N1.N1=CC=CC2=CC=CC=C21 XJPQCGZMDOXKRK-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108020004256 Beta-lactamase Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005940 Bone and joint infections Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- PMFCQQJRGVEDAV-UHFFFAOYSA-N C1=CC=CC=2C3=CC=CC=C3NC12.O1C=NC2=C1C=CC=C2.S2C=NC1=C2C=CC=C1.N1=CNC2=C1C=CC=C2 Chemical compound C1=CC=CC=2C3=CC=CC=C3NC12.O1C=NC2=C1C=CC=C2.S2C=NC1=C2C=CC=C1.N1=CNC2=C1C=CC=C2 PMFCQQJRGVEDAV-UHFFFAOYSA-N 0.000 description 1
- BVKFXTWQAWDQFR-NSODJVPESA-N CC[C@H]([C@H](C)CN(C1)c(c(Br)cc2c3N(C4CC4)C=C(C(O)=O)C2=O)c3Cl)[C@@H]1N Chemical compound CC[C@H]([C@H](C)CN(C1)c(c(Br)cc2c3N(C4CC4)C=C(C(O)=O)C2=O)c3Cl)[C@@H]1N BVKFXTWQAWDQFR-NSODJVPESA-N 0.000 description 1
- BQRDJFYWBQEMDC-UHFFFAOYSA-N COc(c(P)c(cc1F)C(Cl)=O)c1F Chemical compound COc(c(P)c(cc1F)C(Cl)=O)c1F BQRDJFYWBQEMDC-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 206010061977 Genital infection female Diseases 0.000 description 1
- DOJXGHGHTWFZHK-UHFFFAOYSA-N Hexachloroacetone Chemical compound ClC(Cl)(Cl)C(=O)C(Cl)(Cl)Cl DOJXGHGHTWFZHK-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- XVBNFGXVURAEFY-UHFFFAOYSA-N N1=CC=NC2=CC=CC=C12.N1=CN=CC2=CC=CC=C12.C1=NN=CC2=CC=CC=C12.N1=NC=CC2=CC=CC=C12.C1=NC=CC2=CC=CC=C12 Chemical compound N1=CC=NC2=CC=CC=C12.N1=CN=CC2=CC=CC=C12.C1=NN=CC2=CC=CC=C12.N1=NC=CC2=CC=CC=C12.C1=NC=CC2=CC=CC=C12 XVBNFGXVURAEFY-UHFFFAOYSA-N 0.000 description 1
- LKPFLVYHEJATCG-UHFFFAOYSA-N N1CCOCC1.N1CCCCC1.O1C=NCCC1 Chemical compound N1CCOCC1.N1CCCCC1.O1C=NCCC1 LKPFLVYHEJATCG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000038458 Nepenthes mirabilis Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- BTEJIQIWRRQYSK-UHFFFAOYSA-N S(=O)(=O)(O)O.O=C1C(C=NC2=CC=CC=C12)C(=O)O Chemical compound S(=O)(=O)(O)O.O=C1C(C=NC2=CC=CC=C12)C(=O)O BTEJIQIWRRQYSK-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001312524 Streptococcus viridans Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NQPSKPGQESKQCB-QWRGUYRKSA-N [(2s,4s)-2-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-methylsulfonyloxypentyl] methanesulfonate Chemical compound CS(=O)(=O)OC[C@@H](C)C[C@@H](COS(C)(=O)=O)NC(=O)OC(C)(C)C NQPSKPGQESKQCB-QWRGUYRKSA-N 0.000 description 1
- RQDHZOULIZSPHN-UHFFFAOYSA-N [2,6-difluoro-4-[(2-methylpropan-2-yl)oxy]-5-nitropyridin-3-yl]-trimethylstannane Chemical compound CC(C)(C)OC1=C([N+]([O-])=O)C(F)=NC(F)=C1[Sn](C)(C)C RQDHZOULIZSPHN-UHFFFAOYSA-N 0.000 description 1
- MESNMAPDQJTKMY-UHFFFAOYSA-N [3,6-difluoro-5-methyl-4-[(2-methylpropan-2-yl)oxy]pyridin-2-yl]hydrazine Chemical compound CC1=C(F)N=C(NN)C(F)=C1OC(C)(C)C MESNMAPDQJTKMY-UHFFFAOYSA-N 0.000 description 1
- LCYCBVFREHDCRH-UHFFFAOYSA-N [chloro(phenoxy)methylidene]-cyclopropylimino-$l^{4}-sulfane Chemical compound C1CC1N=S=C(Cl)OC1=CC=CC=C1 LCYCBVFREHDCRH-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical compound NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 description 1
- UFWCPDSEOVJAEA-UHFFFAOYSA-N amino-[3-chloro-2-(cyclopropylamino)-4,5-difluorobenzoyl]carbamic acid Chemical compound OC(=O)N(N)C(=O)C1=CC(F)=C(F)C(Cl)=C1NC1CC1 UFWCPDSEOVJAEA-UHFFFAOYSA-N 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 238000007080 aromatic substitution reaction Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000000656 azaniumyl group Chemical group [H][N+]([H])([H])[*] 0.000 description 1
- KLJHWFLIVBRHTG-UHFFFAOYSA-N azetidine aziridine 1,4-oxathiane oxetane oxirane oxolane pyrrolidine Chemical compound O1CCSCC1.N1CCCC1.O1CCCC1.N1CCC1.O1CCC1.N1CC1.O1CC1 KLJHWFLIVBRHTG-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- PNPBGYBHLCEVMK-UHFFFAOYSA-L benzylidene(dichloro)ruthenium;tricyclohexylphosphane Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1P(C1CCCCC1)C1CCCCC1.C1CCCCC1P(C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-L 0.000 description 1
- PNPBGYBHLCEVMK-UHFFFAOYSA-N benzylidene(dichloro)ruthenium;tricyclohexylphosphanium Chemical compound Cl[Ru](Cl)=CC1=CC=CC=C1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1.C1CCCCC1[PH+](C1CCCCC1)C1CCCCC1 PNPBGYBHLCEVMK-UHFFFAOYSA-N 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- QHTOIDKCEPKVCM-ZCFIWIBFSA-N cepham Chemical compound S1CCCN2C(=O)C[C@H]21 QHTOIDKCEPKVCM-ZCFIWIBFSA-N 0.000 description 1
- 150000001782 cephems Chemical class 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- NWFNSTOSIVLCJA-UHFFFAOYSA-L copper;diacetate;hydrate Chemical compound O.[Cu+2].CC([O-])=O.CC([O-])=O NWFNSTOSIVLCJA-UHFFFAOYSA-L 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 210000002895 cranial sinus Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- HTFFABIIOAKIBH-UHFFFAOYSA-N diazinane Chemical compound C1CCNNC1 HTFFABIIOAKIBH-UHFFFAOYSA-N 0.000 description 1
- SBTVCCZEDARAEG-UHFFFAOYSA-N dipotassium;trimethylsilylazanide Chemical compound [K+].[K+].C[Si](C)(C)[NH-].C[Si](C)(C)[NH-] SBTVCCZEDARAEG-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- UAELSWPMQFFVHB-UHFFFAOYSA-N ethyl 2-(2,6-dichloro-5-fluoropyridine-3-carbonyl)-3-ethoxyprop-2-enoate Chemical compound CCOC=C(C(=O)OCC)C(=O)C1=CC(F)=C(Cl)N=C1Cl UAELSWPMQFFVHB-UHFFFAOYSA-N 0.000 description 1
- DGPCYARVYWTXBL-UHFFFAOYSA-N ethyl 2-(cyclopropylamino)-4,5-difluoro-3-methylbenzoate Chemical compound CCOC(=O)C1=CC(F)=C(F)C(C)=C1NC1CC1 DGPCYARVYWTXBL-UHFFFAOYSA-N 0.000 description 1
- HMQOVFDOJIDVFA-UHFFFAOYSA-N ethyl 2-[2-(4-chloro-3-methyl-5-nitropyridin-2-yl)cyclopropyl]acetate Chemical compound CCOC(=O)CC1CC1C1=NC=C([N+]([O-])=O)C(Cl)=C1C HMQOVFDOJIDVFA-UHFFFAOYSA-N 0.000 description 1
- RAPUFVUTVQLBEW-UHFFFAOYSA-N ethyl 3-(cyclopropylamino)-2-(2,6-dichloro-5-fluoropyridine-3-carbonyl)prop-2-enoate Chemical compound C=1C(F)=C(Cl)N=C(Cl)C=1C(=O)C(C(=O)OCC)=CNC1CC1 RAPUFVUTVQLBEW-UHFFFAOYSA-N 0.000 description 1
- KWDVJYLIAJHEOW-UHFFFAOYSA-N ethyl 3-oxo-3-(2,3,4,5-tetrafluorophenyl)propanoate Chemical compound CCOC(=O)CC(=O)C1=CC(F)=C(F)C(F)=C1F KWDVJYLIAJHEOW-UHFFFAOYSA-N 0.000 description 1
- WTKWXCRLEWADRT-UHFFFAOYSA-N ethyl 3-oxo-3-(2,4,5-trifluoro-3-methoxyphenyl)propanoate Chemical compound CCOC(=O)CC(=O)C1=CC(F)=C(F)C(OC)=C1F WTKWXCRLEWADRT-UHFFFAOYSA-N 0.000 description 1
- UKWTVZWBUMIVGD-UHFFFAOYSA-N ethyl 4,5-difluoro-2-nitro-3-trimethylstannylbenzoate Chemical compound CCOC(=O)C1=CC(F)=C(F)C([Sn](C)(C)C)=C1[N+]([O-])=O UKWTVZWBUMIVGD-UHFFFAOYSA-N 0.000 description 1
- VKRGFYDDFCUZIP-UHFFFAOYSA-N ethyl 4,5-difluoro-3-methyl-2-nitrobenzoate Chemical compound CCOC(=O)C1=CC(F)=C(F)C(C)=C1[N+]([O-])=O VKRGFYDDFCUZIP-UHFFFAOYSA-N 0.000 description 1
- ROIRWNGWIWZBOJ-UHFFFAOYSA-N ethyl 6-bromo-8-chloro-1-cyclopropyl-7-fluoro-4-oxoquinoline-3-carboxylate Chemical compound C12=C(Cl)C(F)=C(Br)C=C2C(=O)C(C(=O)OCC)=CN1C1CC1 ROIRWNGWIWZBOJ-UHFFFAOYSA-N 0.000 description 1
- RWCZOVMOKFTUAD-UHFFFAOYSA-N ethyl 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylate Chemical compound C12=NC(Cl)=C(F)C=C2C(=O)C(C(=O)OCC)=CN1C1CC1 RWCZOVMOKFTUAD-UHFFFAOYSA-N 0.000 description 1
- BFALHRFVDOUOBY-UHFFFAOYSA-N ethyl 8-chloro-1-cyclopropyl-9-methyl-7-nitro-4-oxoquinolizine-3-carboxylate Chemical compound C=12C(C)=C(Cl)C([N+]([O-])=O)=CN2C(=O)C(C(=O)OCC)=CC=1C1CC1 BFALHRFVDOUOBY-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- LJCHSZRTMJEOKW-UHFFFAOYSA-N furan 1H-imidazole 1,2-oxazole 1,3-oxazole 1H-pyrazole 1H-pyrrole thiophene Chemical compound O1C=NC=C1.O1N=CC=C1.N1C=NC=C1.N1N=CC=C1.S1C=CC=C1.O1C=CC=C1.N1C=CC=C1 LJCHSZRTMJEOKW-UHFFFAOYSA-N 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 244000000059 gram-positive pathogen Species 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000003752 hydrotrope Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- XLUOEAYOBDICRA-UHFFFAOYSA-N n-[tert-butyl(dimethyl)silyl]-2-methylpropan-2-amine Chemical compound CC(C)(C)N[Si](C)(C)C(C)(C)C XLUOEAYOBDICRA-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 206010033072 otitis externa Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- 229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
- HHXMXAQDOUCLDN-RXMQYKEDSA-N penem Chemical compound S1C=CN2C(=O)C[C@H]21 HHXMXAQDOUCLDN-RXMQYKEDSA-N 0.000 description 1
- 150000002961 penems Chemical class 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- MYHOHFDYWMPGJY-UHFFFAOYSA-N pentafluorobenzoyl chloride Chemical compound FC1=C(F)C(F)=C(C(Cl)=O)C(F)=C1F MYHOHFDYWMPGJY-UHFFFAOYSA-N 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- UPKZHYGHYKBUAC-UHFFFAOYSA-N pyrazine pyridazine pyrimidine 1,3,5-triazine Chemical compound N1=CN=CN=C1.N1=CC=NC=C1.N1=CN=CC=C1.N1=NC=CC=C1 UPKZHYGHYKBUAC-UHFFFAOYSA-N 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000005554 pyridyloxy group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 description 1
- NJTTVQNWCHVKBO-UHFFFAOYSA-N tert-butyl n-(6-azaspiro[3.5]nonan-8-yl)carbamate Chemical compound C1C(NC(=O)OC(C)(C)C)CNCC11CCC1 NJTTVQNWCHVKBO-UHFFFAOYSA-N 0.000 description 1
- RPVYZWNLAKAAKR-UHFFFAOYSA-N tert-butyl n-(6-benzyl-6-azaspiro[3.5]nonan-8-yl)carbamate Chemical compound C1C2(CCC2)CC(NC(=O)OC(C)(C)C)CN1CC1=CC=CC=C1 RPVYZWNLAKAAKR-UHFFFAOYSA-N 0.000 description 1
- NMILHHIJVFGDCA-RDJZCZTQSA-N tert-butyl n-[(3s,5s)-1-benzyl-5-ethylpiperidin-3-yl]carbamate Chemical compound C1[C@@H](CC)C[C@H](NC(=O)OC(C)(C)C)CN1CC1=CC=CC=C1 NMILHHIJVFGDCA-RDJZCZTQSA-N 0.000 description 1
- XCMHWWZDAXHISG-HOCLYGCPSA-N tert-butyl n-[(3s,5s)-1-benzyl-5-methylpiperidin-3-yl]carbamate Chemical compound C1[C@@H](C)C[C@H](NC(=O)OC(C)(C)C)CN1CC1=CC=CC=C1 XCMHWWZDAXHISG-HOCLYGCPSA-N 0.000 description 1
- MUCIWXKVMWBVLL-MYJWUSKBSA-N tert-butyl n-[(8r)-5-benzyl-8-methyl-5-azaspiro[2.5]octan-7-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC([C@@H](C1(CC1)C1)C)CN1CC1=CC=CC=C1 MUCIWXKVMWBVLL-MYJWUSKBSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Substances C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- 238000007514 turning Methods 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Definitions
- the subject invention relates to novel antimicrobial compounds, their compositions and their uses.
- the chemical and medical literature describes compounds that are said to be antimicrobial, i.e., capable of destroying or suppressing the growth or reproduction of microorganisms, such as bacteria.
- antimicrobials and other antimicrobials are described in Antibiotics. Chemotherapeutics. and Antibacterial Agents for Disease Control (M. Grayson, editor, 1982), and E. Gale et al., The Molecular Basis of Antibiotic Action 2d edition (1981).
- beta-lactam antibacterials act through inhibiting the essential penicillin binding proteins (PBPs) in bacteria, which are responsible for cell wall synthesis.
- PBPs penicillin binding proteins
- quinolones act, at least in part, by inhibiting synthesis of DNA, thus preventing the cell from replicating.
- antimicrobials The pharmacological characteristics of antimicrobials, and their suitability for any given clinical use, vary.
- the classes of antimicrobials may vary in 1) their relative efficacy against different types of microorganisms, 2) their susceptibility to development of microbial resistance and 3) their pharmacological characteristics, such as their bioavailability, and biodistribution. Accordingly, selection of an appropriate antibacterial (or other antimicrobial) in a given clinical situation requires analysis of many factors, including the type of organism involved, the desired method of administration, the location of the infection to be treated and other considerations.
- Domagala et al. "Quinolone Antibacterials Containing the New 7-[3-(l-Aminoethyl)-l- pyrrolidinyl] Side Chain: The Effects of the 1-Aminoethyl Moiety and Its Stereochemical Configurations on Potency and in Vivo Efficacy", J. Med. Chem.. Vol. 36, pp. 871-882 (1993); Hagen et al., “Synthesis and Antibacterial Activity of New Quinolones Containing a 7-[3-(l- Amino-l-methylethyl)-l- ⁇ yrrolidinyl] Moiety.
- Resistance can be defined as existence of organisms, within a population of a given microbial species, that are less susceptible to the action of a given antimicrobial agent. This resistance is of particular concern in environments such as hospitals and nursing homes, where relatively high rates of infection and intense use of antibacterials are common. See, e.g., W. Sanders, Jr. et al., "Inducible Beta- lactamases: Clinical and Epidemiologic Implications for Use of Newer Cephalosporins", Reviews of Infectious Diseases, p. 830 (1988).
- Pathogenic bacteria are known to acquire resistance via several distinct mechanisms including inactivation of the antibiotic by bacterial enzymes (e.g., b-lactamases hydrolyzing penicillin and cephalosporins); removal of the antibiotic using efflux pumps; modification of the target of the antibiotic via mutation and genetic recombination (e.g., penicillin-resistance in Neiserria gonorrhoeae); and acquisition of a readily transferable gene from an external source to create a resistant target (e.g., methicillin-resistance in Staphylococcus aureus).
- bacterial enzymes e.g., b-lactamases hydrolyzing penicillin and cephalosporins
- removal of the antibiotic using efflux pumps e.g., penicillin-resistance in Neiserria gonorrhoeae
- modification of the target of the antibiotic via mutation and genetic recombination e.g., penicillin-resistance in Neiserria gonorrh
- gatifloxacin ( ⁇ )-l-cyclopropyl-6-fluoro-l,4- dihydro-8-methoxy-7-(3-methyl-l- ⁇ iperazinyl)-4-oxo-3-quinoline carboxylic acid) is reported to exhibit clastogenicity, Jounal of Antimicrobial Chemotherapy, Vol. 33, pp. 685-706 (1994). Hence existing antibacterials have demonstrated undesirable side effects such as clastogenicity
- antimicrobials with useful properties, including a favorable clastogenecity profile, which can be used against resistant microbes.
- a 1 is selected from -N- and -C(R 8 )-, where R 8 is selected from hydrogen, halo, C ⁇ to about Cg alkyl, C2 to about Cg alkene or alkyne and Cj to about Cg alkoxy, all such alkyl, alkene, alkyne and alkoxy moieties being unsubstituted or substituted with from 1 to about 3 fluoro;
- Y is selected from -N(R X )- and -CR°R 1 -; wherein R° is selected from hydrogen and nil, wherein R° is hydrogen when b is single bond and R° is nil when b is a double bond;
- (c) Z is selected from -C(COR 3 )- , -N(R 3 )- and -N(NHR 3 )-; where (i) if Z is - C(COR 3 )-, c is a double bond, and (ii) if Z is either -N(R 3 )- and -N(NHR 3 )-, c is a single bond;
- R 1 is selected from C3 to about Cg cycloalkyl, C 3 to about Cg heterocycloalkyl, C ⁇ to about Cg alkyl, C2 to about Cg alkene or alkyne, C ⁇ to about Cg alkyloxy, 6- membered aryl and 6-membered heteroaryl, all such alkyl, alkene, alkyne, alkoxy, cycloalkyl, aryl and heteroaryl being unsubstituted or substituted with from 1 to 3 fluoro, all such aryl and heteroaryl also being unsubstituted or substituted with one hydroxy in the 4-position;
- R 2 is selected from hydrogen, double bond oxygen, C to about Cg alkyl, C2 to about Cg alkene or alkyne, C ⁇ to about Cg alkoxy and C to about Cg thioalkyl; provided that R 2 is double bond oxygen only if Z is either -N(OH)- or -N(NHR 3
- R 3 is selected from hydrogen, hydroxy, C to about Cg alkyl, C2 to about Cg alkene or alkyne, C ⁇ to about Cg alkoxy and C ⁇ to about Cg thioalkyl;
- R s is selected from hydrogen, hydroxy, amino, halo, C to about Cg alkyl, C2 to about C4 alkene or alkyne and C ⁇ to about C4 alkoxy, all such alkyl, alkene, alkyne and alkoxy moieties being unsubstituted or substituted with from 1 to 3 fluoro;
- R 6 is selected from hydroxy, aminocarbonyl, fluoro, chloro, bromo, cyano, C ⁇ to about C2 alkyl and C2 to about C4 alkenyl or alkynyl, all such alkyl, alkenyl and alkynyl moieties being unsubstituted or substituted with from 1 to about 3 fluoro;
- R 7 and R 7 are each independently selected from:
- R 7 and R 7 join to form a C3 to about Cg cycloalkyl or heterocyclic ring containing the carbon atom to which they are bonded;
- R 9 and R 9 are each independently selected from hydrogen and Ci to about C3 alkyl, or R 9 and R 9 join to form a C3 to about Cg heterocyclic ring containing the nitrogen atom to which they are bonded;
- R 10 represents the moieties on the piperidine ring other than R 7 , R 7 and -NR 9 R 9 , where each R 10 is independently selected from hydrogen, C ⁇ to about Cg alkyl, C2 to about Cg alkene or alkyne, C ⁇ to about Cg alkoxy and C3-Cg cycloalkyl all such alkyl, alkene, alkyne, alkoxy and cycloalkyl moieties being unsubstituted or substituted with from 1 to 3 fluoro; or (B) if A 1 is -C(R 8 )-, X is -C- and Y is -NCR 1 )-, then R 8 and R 1 can join to form a 6-membered heterocyclic ring, where R 2 , R 3 , R 5 , R 6 , R 7 , R 7' , R 9 , R 9' and R 10 are as described in (A); or (C) if A 1 is -C(R 8
- R 2 and R 3 can join to form a 5-membered heterocycloalkyl that is substituted with a carbonyl moiety, where R 1 , R 5 , R 6 , R 7 , R 7' ,R 8 , R 9 , R 9' and R 10 are as described in (A); or an optical isomer, diastereomer or enantiomer thereof; a pharmaceutically-acceptable salt, hydrate, or biohydrolyzable ester, amide or imide thereof.
- compounds incorporating the compounds of the invention, or using compounds of the invention as starting materials are also contemplated in this invention.
- the compounds of this invention are effective antimicrobial agents against a broad range of pathogenic microorganisms with advantages in low susceptibility to microbial resistance, reduced toxicity, and improved pharmacology.
- Preferred acyl groups include (for example) acetyl, formyl, and propionyl.
- Alkyl is a saturated hydrocarbon chain having 1 to 15 carbon atoms, preferably 1 to 10, more preferably 1 to 4 carbon atoms.
- Alkene is a hydrocarbon chain having at least one (preferably only one) carbon-carbon double bond and having 2 to 15 carbon atoms, preferably 2 to 10, more preferably 2 to 4 carbon atoms.
- Alkyne is a hydrocarbon chain having at least one (preferably only one) carbon-carbon triple bond and having 2 to 15 carbon atoms, preferably 2 to 10, more preferably 2 to 4 carbon atoms.
- Alkyl, alkene and alkyne chains (referred to collectively as "hydrocarbon chains”) may be straight or branched and may be unsubstituted or substituted.
- Preferred branched alkyl, alkene and alkyne chains have one or two branches, preferably one branch.
- Preferred chains are alkyl.
- Alkyl, alkene and alkyne hydrocarbon chains each may be unsubstituted or substituted with from 1 to 4 substituents; when substituted, preferred chains are mono-, di-, or tri-substituted.
- Alkyl, alkene and alkyne hydrocarbon chains each may be substituted with halo, hydroxy, aryloxy (e.g., phenoxy), heteroaryloxy, acyloxy (e.g., acetoxy), carboxy, aryl (e.g., phenyl), heteroaryl, cycloalkyl, heterocycloalkyl, spirocycle, amino, amido, acylamino, keto, thioketo, cyano, or any combination thereof.
- Preferred hydrocarbon groups include methyl, ethyl, propyl, isopropyl, butyl, vinyl, allyl, butenyl, and exomethylenyl.
- Alkoxy is an oxygen radical having a hydrocarbon chain substituent, where the hydrocarbon chain is an alkyl or alkenyl (i.e., -O-alkyl or -O-alkenyl).
- Preferred alkoxy groups include (for example) methoxy, ethoxy, propoxy and allyloxy.
- Alkylthio is -S-alkyl (e.g. -S-CH 3 ).
- a “lower” alkoxy, alkylthio, alkyl, alkene or alkyne moiety is a chain comprised of 1 to 6, preferably from 1 to 4, carbon atoms in the case of alkyl, alkoxy and alkylthio, and 2 to 6, preferably 2 to 4, carbon atoms in the case of alkene and alkyne.
- Amino refers to a primary (-NH 2 ), secondary (-NH(alkyl), also referred to herein as “alkylamino”) or tertiary (-N(alkyl) 2 ,also referred to herein as “dialkylamino”).
- Aminoalkyl is an alkyl moiety substituted with an amino, alkyl amino or dialkyl amino group (e.g., -CH 2 NH 2 , -CH 2 CH 2 NH 2 , -CH 2 NHCH 3 , -CH 2 N(CH 3 ) 2 ).
- Aryl is an aromatic hydrocarbon ring.
- Aryl rings are monocyclic or fused bicyclic ring systems.
- Monocyclic aryl rings contain 6 carbon atoms in the ring.
- Monocyclic aryl rings are also referred to as phenyl rings.
- Bicyclic aryl rings contain from 8 to 17 carbon atoms, preferably 9 to 12 carbon atoms, in the ring.
- Bicyclic aryl rings include ring systems wherein one ring is aryl and the other ring is aryl, cycloalkyl, or heterocycloakyl.
- Preferred bicyclic aryl rings comprise 5-, 6- or 7-membered rings fused to 5-, 6-, or 7-membered rings.
- Aryl rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring.
- Aryl may be substituted with halo, cyano, nitro, hydroxy, carboxy, amino, acylamino, alkyl, heteroalkyl, haloalkyl, phenyl, aryloxy, alkoxy, heteroalkyloxy, carbamyl, haloalkyl, methylenedioxy, heteroaryloxy, or any combination thereof.
- Preferred aryl rings include naphthyl, tolyl, xylyl, and phenyl. The most preferred aryl ring radical is phenyl.
- Aryloxy is an oxygen radical having an aryl substituent (i.e., -O-aryl).
- Preferred aryloxy groups include (for example) phenoxy, napthyloxy, methoxyphenoxy, and methylenedioxyphenoxy.
- Carbocyclic ring encompasses both cycloalkyl and aryl moieties, as those terms are defined herein.
- Cycloalkyl is a saturated or unsaturated hydrocarbon ring. Cycloalkyl rings are not aromatic. Cycloalkyl rings are monocyclic, or are fused, spiro, or bridged bicyclic ring systems. Monocyclic cycloalkyl rings contain from about 3 to about 9 carbon atoms, preferably from 3 to 7 carbon atoms, in the ring. Bicyclic cycloalkyl rings contain from 7 to 17 carbon atoms, preferably from 7 to 12 carbon atoms, in the ring. Preferred bicyclic cycloalkyl rings comprise 4-, 5-, 6- or 7-membered rings fused to 5-, 6-, or 7-membered rings.
- Cycloalkyl rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring. Cycloalkyl may be substituted with halo, cyano, alkyl, heteroalkyl, haloalkyl, phenyl, keto, hydroxy, carboxy, amino, acylamino, aryloxy, heteroaryloxy, or any combination thereof. Preferred cycloalkyl rings include cyclopropyl, cyclopentyl, and cyclohexyl.
- Halo or "halogen” is fluoro, chloro, bromo or iodo. Preferred halo are fluoro, chloro and bromo; more preferred typically are chloro and fluoro, especially fluoro.
- Haloalkyl is a straight, branched, or cyclic hydrocarbon substituted with one or more halo substituents. Preferred are C1-C12 haloalkyls; more preferred are Cj-Cg haloalkyls; still more preferred still are C1-C3 haloalkyls. Preferred halo substituents are fluoro and chloro. The most preferred haloalkyl is trifluoromethyl.
- Heteroatom is a nitrogen, sulfur, or oxygen atom. Groups containing more than one heteroatom may contain different heteroatoms.
- Heteroalkyl is a saturated or unsaturated chain containing carbon and at least one heteroatom, wherein no two heteroatoms are adjacent. Heteroalkyl chains contain from 2 to 15 member atoms (carbon and heteroatoms) in the chain, preferably 2 to 10, more preferably 2 to 5. For example, alkoxy (i.e., -O-alkyl or -O-heteroalkyl) radicals are included in heteroalkyl. Heteroalkyl chains may be straight or branched. Preferred branched heteroalkyl have one or two branches, preferably one branch. Preferred heteroalkyl are saturated. Unsaturated heteroalkyl have one or more carbon-carbon double bonds and/or one or more carbon-carbon triple bonds.
- Preferred unsaturated heteroalkyls have one or two double bonds or one triple bond, more preferably one double bond.
- Heteroalkyl chains may be unsubstituted or substituted with from 1 to 4 substituents.
- Preferred substituted heteroalkyl are mono-, di-, or tri-substituted.
- Heteroalkyl may be substituted with lower alkyl, haloalkyl, halo, hydroxy, aryloxy, heteroaryloxy, acyloxy, carboxy, monocyclic aryl, heteroaryl, cycloalkyl, heterocycloalkyl, spirocycle, amino, acylamino, amido, keto, thioketo, cyano, or any combination thereof.
- Heteroaryl is an aromatic ring containing carbon atoms and from 1 to about 6 heteroatoms in the ring. Heteroaryl rings are monocyclic or fused bicyclic ring systems. Monocyclic heteroaryl rings contain from about 5 to about 9 member atoms (carbon and heteroatoms), preferably 5 or 6 member atoms, in the ring. Bicyclic heteroaryl rings contain from 8 to 17 member atoms, preferably 8 to 12 member atoms, in the ring. Bicyclic heteroaryl rings include ring systems wherein one ring is heteroaryl and the other ring is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl.
- Preferred bicyclic heteroaryl ring systems comprise 5-, 6- or 7-membered rings fused to 5-, 6-, or 7-membered rings.
- Heteroaryl rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring.
- Heteroaryl may be substituted with halo, cyano, nitro, hydroxy, carboxy, amino, acylamino, alkyl, heteroalkyl, haloalkyl, phenyl, alkoxy, aryloxy, heteroaryloxy, or any combination thereof.
- Preferred heteroaryl rings include, but are not limited to, the following:
- Heteroaryloxy is an oxygen radical having a heteroaryl substituent (i.e., -O-heteroaryl).
- Preferred heteroaryloxy groups include (for example) pyridyloxy, furanyloxy, (thiophene)oxy, (oxazole)oxy, (thiazole)oxy, (isoxazole)oxy, pyrmidinyloxy, pyrazinyloxy, and benzothiazolyloxy.
- Heterocycloalkyl is a saturated or unsaturated ring containing carbon atoms and from 1 to about 4 (preferably 1 to 3) heteroatoms in the ring. Heterocycloalkyl rings are not aromatic. Heterocycloalkyl rings are monocyclic or bicyclic ring systems. Monocyclic heterocycloalkyl rings contain from about 3 to about 9 member atoms (carbon and heteroatoms), preferably from 5 to 7 member atoms, in the ring. Bicyclic heterocycloalkyl rings contain from 7 to 17 member atoms, preferably 7 to 12 member atoms, in the ring.
- Bicyclic heterocycloalkyl rings contain from about 7 to about 17 ring atoms, preferably from 7 to 12 ring atoms. Bicyclic heterocycloalkyl rings may be fused, spiro, or bridged ring systems. Preferred bicyclic heterocycloalkyl rings comprise 5-, 6- or 7-membered rings fused to 5-, 6-, or 7-membered rings. Heterocycloalkyl rings may be unsubstituted or substituted with from 1 to 4 substituents on the ring.
- Heterocycloalkyl may be substituted with halo, cyano, hydroxy, carboxy, keto, thioketo, amino, acylamino, acyl, amido, alkyl, heteroalkyl, haloalkyl, phenyl, alkoxy, aryloxy or any combination thereof.
- Preferred substituents on heterocycloalkyl include halo and haloalkyl.
- Preferred heterocycloalkyl rings include, but are not limited to, the following:
- Oxirane Aziridine Oxetane Azetidine Tetrahydrofuran Pyrrolidine 1 ,4-Oxathiane
- Heterocyclic ring encompasses both hetercycloalkyl and heteroaryl moieties, as those terms are defined herein.
- “Spirocycle” is an alkyl or heteroalkyl diradical substituent of alkyl or heteroalkyl wherein said diradical substituent is attached geminally and wherein said diradical substituent forms a ring, said ring containing 4 to 8 member atoms (carbon or heteroatom), preferably 5 or 6 member atoms.
- “Lower” alkoxy, alkylthio, alkyl, alkene or alkyne moiety is a chain comprised of 1 to 6, preferaby from 1 to 4, carbon atoms in the case of alkyl, alkoxy and alkylthio, and 2 to 6, preferably 2 to 4, carbon atoms in the case of alkene and alkyne.
- alkyl, heteroalkyl, cycloalkyl, and heterocycloalkyl groups may be substituted with hydroxy, amino, and amido groups as stated above, the following are not envisioned in the invention:
- a "pharmaceutically-acceptable salt” is a cationic salt formed at any acidic (e.g., carboxyl) group, or an anionic salt formed at any basic (e.g., amino, alkylamino, dialkylamino, morphylino, and the like) group on the compound of the invention. Since many of the compounds of the invention are zwitterionic, either salt is possible and acceptable. Many such salts are known in the art.
- Preferred cationic salts include the alkali metal salts (such as sodium and potassium), alkaline earth metal salts (such as magnesium and calcium) and organic salts, such as ammonio.
- Preferred anionic salts include halides, sulfonates, carboxylates, phosphates, and the like.
- addition salts that may provide an optical center, where once there is none.
- a chiral tartrate salt may be prepared from the compounds of the invention, and this definition includes such chiral salts.
- Salts contemplated are nontoxic in the amounts administered to the patient-animal, mammal or human.
- the compounds of the invention are sufficiently basic to form acid-addition salts.
- the compounds are useful both in the free-base form and the form of acid-addition salts, and both forms are within the purview of the invention.
- the acid-addition salts are in some cases a more convenient form for use.
- Acids used to prepare acid-addition salts include preferably those which produce, when combined with the free base, medicinally acceptable salts. These salts have anions that are relatively innocuous to the animal organism, such as a mammal, in medicinal doses of the salts so that the beneficial property inherent in the free base are not vitiated by any side effects ascribable to the acid's anions.
- acids-addition salts include, but are not limited to hydrochloride, hydrobromide, hydroiodide, sulfate, hydrogensulfate, acetate, trifluoroacetate, nitrate, citrate, fumarate, formate, stearate, succinate, maleate, malonate, adipate, glutarate, lactate, propionate, butyrate, tartrate, methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate, dodecyl sulfate, cyclohexanesulfamate, and the like.
- the acid-addition salts of the basic compounds are prepared by several methods.
- the free base can be dissolved in an aqueous alcohol solution containing the appropriate acid and the salt is isolated by evaporation of the solution.
- they may be prepared by reacting the free base with an acid in an organic solvent so that the salt separates directly. Where separation of the salt is difficult, it can be precipitated with a second organic solvent, or can be obtained by concentration of the solution.
- “Host” is a substrate capable of sustaining a microbe, preferably it is a living organism, more preferably an animal, more preferably a mammal, more preferably still a human.
- Biohydrolyzable amides are aminoacyl, acylamino, or other amides of the compounds of the invention, where the amide does not essentially interfere, preferably does not interfere, with the activity of the compound, or where the amide is readily converted in vivo by a host to yield an active compound.
- Biohydrolyzable imides are imides of compounds of the invention, where the imide does not essentially interfere, preferably does not interfere, with the activity of the compound, or where the imide is readily converted in vivo by a host to yield an active compound.
- Preferred imides are hydroxyimides.
- Biohydrolyzable esters are esters of compounds of the invention, where the ester does not essentially interfere, preferably does not interfere, with the antimicrobial activity of the compound, or where the ester is readily converted in a host to yield an active compound. Many such esters are known in the art, as described in U.S. Patent No. 4,783,443, issued to Johnston and Mobashery on November 8, 1988 (incorporated by reference herein).
- esters include lower alkyl esters, lower acyloxy-alkyl esters (such as acetoxymethyl, acetoxyethyl, aminocarbonyloxymethyl, pivaloyloxymethyl and pivaloyloxyethyl esters), lactonyl esters (such as phthalidyl and thiophthalidyl esters), lower alkoxyacyloxyalkyl esters (such as methoxycarbonyloxymethyl, ethoxycarbonyloxyethyl and isopropoxycarbonyloxyethyl esters), alkoxyalkyl esters, choline esters and alkylacylaminoalkyl esters (such as acetamidomethyl esters).
- lower alkyl esters such as acetoxymethyl, acetoxyethyl, aminocarbonyloxymethyl, pivaloyloxymethyl and pivaloyloxyethyl esters
- lactonyl esters such as phthalid
- a “solvate” is a complex formed by the combination of a solute (e.g., a quinolone) and a solvent (e.g., water). See J. Honig et al., The Van Nostrand Chemist's Dictionary, p. 650 (1953).
- Pharmaceutically-acceptable solvents used according to this invention include those that do not interfere with the biological activity of the quinolone or quinolone derivative (e.g., water, ethanol, acetic acid, N,N-dimethylformamide and others known or readily determined by the skilled artisan).
- optical isomer “optical isomer”, “stereoisomer”, and “diastereomer” have the standard art recognized meanings (see, e.g., Hawley's Condensed Chemical Dictionarv. 11th Ed.).
- the illustration of specific protected forms and other derivatives of the compounds of the instant invention is not intended to be limiting.
- the application of other useful protecting groups, salt forms, etc. is within the ability of the skilled artisan.
- the compounds of the invention may have one or more chiral centers.
- one optical isomer including diastereomer and enantiomer
- another optical isomer for example by use of chiral starting materials, catalysts or solvents
- the compounds of the invention may exist as racemic mixtures, mixtures of optical isomers, including diastereomers and enantiomers, or stereoisomers, they may be separated using known methods, such as chiral resolution, chiral chromatography and the like.
- one optical isomer including diastereomer and enantiomer, or stereoisomer may have favorable properties over the other.
- both optical isomers including diastereomers and enantiomers, or stereoisomers substantially free of the other are disclosed and claimed as well.
- a quinolone derivative includes prodrugs of a quinolone, or an active drug made from a quinolone.
- such derivatives include lactams (e.g., cephems, carbacephems, penems, monolactams, etc.) covalently linked to the quinolone optionally via a spacer.
- lactams e.g., cephems, carbacephems, penems, monolactams, etc.
- the subject invention involves compounds of Formula (I):
- nucleus of the compounds will include only two fused rings as depicted.
- nucleus of the compounds will include three or four fused rings, as defined in sub-parts (B) through (D).
- These alternative embodiments are depicted as Formula (D), Formula (E) and Formula (F), Formula (G), and Formula (H) respectively, below.
- Table I contains a non-limiting list of compounds of Formula (A)
- Cy Cyclopropyl
- F-Cy 2-fluorocyclopropyl
- 4F-Ph 4- fluorophenyl
- 2,4diFPh 2,4-difluorophenyl
- Table II contains a non-limiting list of compounds of Formula (B).
- Table HI contains compounds of Formula (C).
- Table IV contains a non-limiting list of compounds according to Formula (D).
- (D) These compounds are those of Formula (I) where Z is -C(COR3)-, R 1 and R s join to form a 6- membered heterocycloalkyl.
- Formula (D) is defined such that D is substituted or unsubstituted - C- or -N- or D is -O- or S; R 13 and R 13 are independently selected from hydrogen and C1-C6 alkyl; and E is selected from -0-, -S-, substituted or unsubstituted -C- and substituted or unsubstituted -N-.
- D is -0-.
- E is -CH 2 -.
- R 13 is hydrogen and R 13 is C1-C6 alkyl, preferably methyl.
- Table V contains a non-limiting list of preferred compounds of Formula (D).
- Formula (E) These compounds are those of Formula (I) where Z is -C(COR3) ⁇ , and R 1 and R 2 join to form ring L, which is a mono- or bicyclic heterocycle comprising N'.
- Table VI contains a non-limiting list of preferred compounds of Formula (F) having the following formula:
- Table VII contains a non-limiting list of preferred compounds of Formula (G) having the following formula:
- the compounds have a structure according to the following structure:
- Formula (H) These compounds are those of Formula (I) where Y is -N(R1)- where R 2 and R 3 of Formula (I) join to form a 5-membered heterocycloalkyl, where T is selected from -O-, -S- and substituted or unsubstituted -N-. In one embodiment, T is -S-.
- Table VIII contains a non-limiting list of preferred compounds of Formula (H).
- a 1 is selected from -N- and -C(R 8 )-.
- a 1 is -C(R 8 )-, where R 8 is selected from hydrogen, halo, C j to about Cg alkyl, C2 to about Cg alkene or alkyne and C j to about Cg alkoxy, all such alkyl, alkene, alkyne and alkoxy moieties being unsubstituted or substituted with from 1 to about 3 fluoro.
- R 8 is hydrogen.
- R 8 is lower alkyl, preferred is where R 8 has from 1 to about 2 carbon atoms; methyl is preferred.
- R 8 is lower alkene, preferred R 8 has from 2 to about 4 carbon atoms; ethenyl is preferred. In one embodiment R 8 is lower alkoxy, preferred R 8 has from 1 to about 4 carbon atoms; methoxy is preferred. In one embodiment R 8 is lower alkylthio, preferred R 8 has from 1 to about 4 carbon atoms, methylthio is preferred. All R 8 alkyl and alkene moieties are unsubstituted or substituted with fluoro. In one embodiment R 8 is halo, preferred R 8 are chloro and fluoro.
- R 8 is selected from chloro, methyl, methoxy, methylthio, monofluoromethyl, difluoromethyl, trifluoromethyl, monofluoromethoxy, difluoromethoxy, and trifluoromethoxy.
- R 8 is selected from methyl substituted with from 1 to 3 fluoro, methoxy, methylthio, and chloro; especially either methoxy, methylthio or chloro.
- a, b and c are each independently a single or double bond.
- a is a double bond
- & is a single bond
- c is a double bond.
- a is a single bond
- b is a double bond
- c is a double bond.
- a is a double bond
- b is a single bond
- c is a double bond.
- a is a double bond
- b is a single bond
- c is a single bond.
- X is selected from -C- or -N-.
- A is a double bond and b is a single bond.
- a is a single bond and b is a double bond.
- Y is selected from -N(R X )- and -CR°R 1 -. However, Y is N(R*) only if X is -C- and Y is - C(R*)- only if X is -N- and Z is -C(COR 3 )-.
- Z is selected from -C(COR 3 )- , -N(R 3 )- and -N(NHR 3 )-.
- Z is -C(COR 3 )-
- c is a double bond.
- Z is either -N(R 3 )- and -N(NHR 3 )-
- c is a single bond.
- Z is either -N(R 3 )- or -N(NHR 3 )- only if X is -C-, Y is -NCR 1 )- and A 1 is -C(R 8 )-.
- R° is selected from hydrogen and nil. When R° is hydrogen, b is single bond. In contrast, when R° is nil, & is a double bond.
- R 1 is selected from C3 to about Cg cycloalkyl, C 3 to about Cg heterocycloalkyl, C j to about Cg alkyl, C2 to about Cg alkene or alkyne, C to about Cg alkyloxy, 6-membered aryl and
- R 1 is selected from C3 to about Cg cycloalkyl, C3 to about Cg heterocycloalkyl, Ci to about C4 alkyl and C2 to about C4 alkene.
- R 1 is selected from cyclopropyl, ethyl, t-butyl, 4- hydroxyphenyl and 2,4-difluorophenyl. In one embodiment R 1 is C3 to about Cg cycloalkyl. In one embodiment, R 1 is C to about C4 alkyl.
- R 1 is cycloalkyl
- rings having from about 3 to about 5 ring carbon atoms, more preferably 3 ring carbon atoms.
- R 1 cycloalkyl moieties are preferably saturated or unsaturated with one double bond; more preferably R 1 cycloalkyl is saturated.
- R 1 is linear lower alkyl, preferred is where R 1 contains from 1 to about 2 carbon atoms; methyl and ethyl are preferred, most preferred is ethyl.
- R 1 is lower linear alkene, preferred is where R 1 contains from 2 to about 3 carbon atoms; ethenyl is preferred.
- R 1 is branched lower alkyl or lower alkene, preferred is where R 1 contains from 3 to about 4 carbon atoms; branched lower alkyl is preferred; t-butyl is particularly preferred. All of the R 1 moieties mentioned in this paragraph are unsubstituted or substituted. When R 1 is substituted, preferred is one or more fluorine atoms.
- R 1 is a 6-membered aryl or a 6-membered heteroaryl aryl
- the ring is unsubstituted or substituted with from 1 to about 3 fluorine atoms, one amino group (preferably at the 3-position of the ring), one hydroxy (preferably in the 4-position of the ring), or a combination of these substituents; substituted phenyl is preferred.
- Preferred R 1 moieties are selected from cyclopropyl, ethyl, phenyl substituted with 1 to 3 fluoro, and 4-hydroxyphenyl; more preferred is 2,4- difluorophenyl, and especially cyclopropyl or ethyl.
- R 1 and R 8 combine to form a fused 6-membered heterocyclic ring
- R 2 is selected from hydrogen, double bond oxygen, C to about Cg alkyl, C2 to about Cg alkene or alkyne, C ⁇ to about Cg alkoxy and C ⁇ to about Cg thioalkyl. However, R 2 is double bond oxygen only if Z is either -N(R 3 )- or -N(NHR 3 )-. In one embodiment, R 2 is hydrogen. In one embodiment R 2 is a double bond oxygen.
- R 1 and R 2 combine to form a fused 6-membered heterocyclic ring.
- R 3 is selected from hydrogen, hydroxy, C ⁇ to about Cg alkyl, C2 to about Cg alkene or alkyne, C j to about Cg alkoxy and Ci to about Cg thioalkyl.
- Z is -C(COR 3 )- and R 3 is selected from hydrogen and hydroxy; preferred is hydroxy thereby forming a carboxylic acid moiety. This carboxylic moiety is a potential point of formation for the subject compounds of pharmaceutically-acceptable salts, and biohydrolizable esters, aminoacyls, and amides, as described herein. Compounds having any such variations at the R 3 position are included in the subject invention.
- Z is -N(R 3 )- and R 3 is hydroxy.
- Z is - N(NHR 3 )- and R 3 is selected from hydrogen, hydroxy and C to about Cg alkyl.
- R 2 and R 3 combine to form a fused 6-membered heterocyclic ring.
- R 5 is selected from hydrogen, hydroxy, amino, halo, C ⁇ to about Cg alkyl, C2 to about C4 alkene or alkyne and C ⁇ to about C4 alkoxy. All such alkyl, alkene, alkyne and alkoxy moieties are unsubstituted or substituted with from 1 to 3 fluoro.
- R 5 is selected from Ci to about C2 alkyl, preferably C ⁇ alkyl.
- R 5 is C2 alkene.
- R 5 is C ⁇ to about C2 alkoxy.
- R 5 is amino. All R s C ⁇ alkyl, C2 alkene and C ⁇ to about C2 alkoxy moieties are unsubstituted or substituted with fluoro moieties.
- R 5 is selected from hydrogen, hydroxy, chloro, bromo, amino, methyl, monofluoromethyl, difluoromethyl and trifluoromethyl. In one embodiment, R 5 is selected from hydrogen, hydroxy, amino, and methyl. In one embodiment, R 5 is hydrogen.
- R 6 is selected from hydroxy, aminocarbonyl, fluoro, chloro, bromo, cyano, C ⁇ to about C2 alkyl and C2 to about C4 alkenyl or alkynyl. All such alkyl, alkenyl and alkynyl moieties are unsubstituted or substituted with from 1 to about 3 fluoro.
- R 6 is selected from hydroxy, fluoro, chloro, bromo, and methyl.
- R 6 is selected from fluoro and chloro.
- R 6 is fluoro.
- R 6 is hydroxy. In oone embodiment R 6 is methyl.
- R 7 and R 7 are each independently selected from hydrogen, C ⁇ to about Cg alkyl, C2 to about
- Cg alkene or alkyne Ci to about Cg alkoxy, C ⁇ to about Cg alkylthio and C to about Cg heteroalkyl; provided R 7 and R 7 are not both hydrogen; or R 7 and R 7 join to form a C3 to about Cg cycloalkyl or heterocyclic ring containing the carbon atom to which they are bonded. All such alkyl, alkene, alkyne, alkoxy, alkythio, heteroalkyl, cycloalkyl and heterocyclic moieties are unsubstituted or substituted with from 1 to 3 fluoro. In one embodiment, R 7 and R 7 join to form a C3 to about Cg cycloalkyl.
- R 7 and R 7 join to form a cyclopropyl.
- R 7 and R 7 are selected from C ⁇ to about C3 alkyl or C ⁇ to about C3 alkyloxy.
- R 7' is hydrogen and R 7 is selected from hydrogen C ⁇ to about C3 alkyl and C to about
- R 7 is hydrogen and R 7 is selected from methoxy, thiomethoxy, methyl and ethyl, all such methoxy, thiomethoxy, methyl and ethyl moieties being unsubstituted or substituted with from 1 to about 3 fluoro. In one embodiment, R 7 is hydrogen and R 7 is selected from methyl and ethyl.
- R 7 is hydrogen and R 7 is selected from Ci to about Cg alkyl, C2 to about Cg alkene or alkyne, C j to about Cg alkoxy, C ⁇ to about Cg alkylthio and Cj to about Cg heteroalkyl and the carbon atom piperidine ring member, to which R 7 is attached, is of the S-configuration.
- R 7 is hydrogen and R 7 is methyl and the carbon atom piperidine ring member, to which R 7 is attached, is of the S-configuration.
- R 9 and R 9 are each independently selected from hydrogen and C ⁇ to about C3 alkyl, or R 9 and R 9 join to form a C3 to about Cg heterocyclic ring containing the nitrogen atom to which they are bonded. In one embodiment R 9 and R 9 are each independently selected from hydrogen, methyl and ethyl. In one embodiment R 9 and R 9 join to form a C3 heterocyclic ring. In one embodiment,
- R 9 and R 9 are each independently selected from hydrogen and methyl. In one embodiment R 9 and R 9 are each hydrogen. In one embodiment, each R 9 and R 9 are each independently selected from hydrogen and methyl, and the carbon atom piperidine ring member, to which -NR 9 R 9 is attached, is of the S-configuration. In one embodiment, R 9 and R 9 are both hydrogen and the carbon atom piperidine ring member, to which -NR 9 R 9 is attached, is of the S-configuration.
- R 10 represents the moieties on the piperidine ring other than R 7 , R 7 and -NR 9 R 9 , where each R 10 is independently selected from hydrogen, C ⁇ to about Cg alkyl, C2 to about Cg alkene or alkyne, C ⁇ to about Cg alkoxy, C3-Cg cycloalkyl all such alkyl, alkene, alkyne, alkoxy and cycloalkyl moieties being unsubstituted or substituted with from 1 to 3 fluoro.
- each R 10 is selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl and methoxy.
- each R 10 is selected from hydrogen, methyl and ethyl.
- each R 10 is hydrogen.
- the carbon atom piperidine ring member to which R 10 is attached is of the S-configeration.
- any radical is independently selected each time it is used (e.g., R 1 and R 5 need not be the same in all occurrences in defining a given compound of this invention).
- the compounds of the invention may contain chiral center(s), thus any such compound includes and contemplates each optical isomer, diastereomer or enantiomer thereof, in purified or substantially purified form, and mixtures thereof, including racemic mixtures.
- the present invention is directed to compounds of Formula (I) wherein X is -C-, Y is -N R 1 )-, Z is -C(COR 1 )-, A is a double bond, b is a single bond, c is a double bond, and R 9 and R 9 are both hydrogen.
- compounds have a structure according to the following Formula (II):
- Formula (II) where A 1 , R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 7' and R 10 are as defined with regard to Formula (I).
- the compounds are those of Formula (II) where A 1 is -C(R 8 )-.
- compounds of Formula (II) are those where R 8 and R 1 do not join to form a ring.
- the present invention is directed to compounds of Formula (I) where X is -N-, A 1 is -C(R 8 )-, Y is -C(R 1 )-, Z is -C(COR 3 )-, a is a single bond, b is a double bond, c is a double bond, and R 9 and R 9 are both hydrogen.
- compounds have a structure according to the following Formula (111):
- Formula (IH) where R 1 , R 2 , R 3 , R s , R 6 , R 7 , R 7' and R 10 are as defined with regard to Formula (I).
- compounds of Formula (lU) are those where R 8 and R 1 do not join to form a ring.
- the present invention is directed to compounds of Formula (I) where X is -C-, A 1 is -C(R 8 )-, Y is -N R 1 )-, R 2 is a double bond oxygen, a is a double bond, b is a single bond, c is a single bond, and R 9 and R 9 are both hydrogen.
- compounds have a structure according to the following Formula (IV):
- R 1 , R 5 , R 6 , R 7 , R 7' , R 8 and R 10 are as defined with regard to Formula (I).
- the subject invention compounds above are also useful precursors for compounds of formula Q-L-B, wherein Q is a compound of Formula I, L is a linking moiety, and B is a lactam- containing moiety.
- This formula includes optical isomers, disatereomers or enantiomers thereof; pharmaceutically-acceptable salts, hydrates, or biohydrolyzable esters, amides and imides thereof.
- Biological activities of the invention compounds can be compared to ciprofloxacin and the other known antimicrobial quinolone compounds.
- Compounds of the subject invention provide better antibacterial properties against certain quinolone resistant bacteria compared to ciprofloxacin and certain other prior art compounds.
- quinolone-resistant bacteria such as S. aureus, S. saprophyticus, E. faecalis, S. pyogenes, S. pneumoniae, S. viridans, E. coli, P. aeruginosa, P. mirabilis, K. pneumoniae, E. cloacae
- certain compounds of the subject invention have been found to have MIC values ( ⁇ g/mL) are lower than ciprofloxacin.
- Clastogenicity profiles of the invention compounds can be compared to glatifloxacin. Certain compounds of the subject invention provide a better clastogenecity profile compared to glatifloxacin and other prior art compounds.
- a suitable clastogenicity assay is described in V. Cigvarino, M. J. Suto, J. C. Thiess, Mutation Research. Vol. 298, p. 227 (1993).
- the order of synthetic steps may be varied to increase yield of desired product.
- the skilled artisan will also recognize the judicious choice of reactants, solvents, and temperatures is an important component in successful synthesis. While the determination of optimal conditions, etc. is routine, it will be understood that a variety of compounds can be generated in a similar fashion, using the guidance of the scheme below. Specific synthetic examples are set forth for a variety of compounds in Section VI.
- the starting materials used in preparing the compounds of the invention are known, made by known methods, or are commercially available as a starting material.
- compositions IV. Compositions:
- compositions of this invention comprise:
- compositions may also optionally comprise other antimicrobials or other actives, which may or may not act synergystically with the invention.
- a "safe and effective amount" of a quinolone is an amount that is effective, to inhibit microbial growth at the site of an infection to be treated in a host, without undue adverse side effects (such as toxicity, irritation, or allergic response), commensurate with a reasonable benefit/risk ratio when used in the manner of this invention.
- the specific "safe and effective amount” will vary with such factors as the particular condition being treated, the physical condition of the patient, the duration of treatment, the nature of concurrent therapy (if any), the specific dosage form to be used, the excipient employed, the solubility of the quinolone therein, and the dosage regimen desired for the composition.
- the compositions of this invention are preferably provided in unit dosage form.
- a "unit dosage form” is a composition of this invention containing an amount of a quinolone that is suitable for administration to a human or lower animal subject, in a single dose, according to good medical practice.
- These compositions preferably contain from about 30 mg, more preferably from about 50 mg, more preferably still from about 100 mg, preferably to about 20,000 mg, more preferably to about 7,000 mg, more preferably still to about 1,000 mg, most preferably to about 500 mg, of a quinolone.
- compositions of this invention may be in any of a variety of forms, suitable (for example) for oral, rectal, topical or parenteral administration.
- a variety of pharmaceutically-acceptable excipients well-known in the art may be used. These include solid or liquid fillers, diluents, hydrotropes, surface-active agents, and encapsulating substances.
- Optional pharmaceutically-active materials may be included, which do not substantially interfere with the antimicrobial activity of the quinolone.
- the amount of excipient employed in conjunction with the quinolone is sufficient to provide a practical quantity of material for administration per unit dose of the quinolone.
- pharmaceutically-acceptable excipients for systemic administration include sugars, starches, cellulose and its derivatives, malt, gelatin, talc, calcium sulfate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffer solutions, emulsifiers, isotonic saline, and pyrogen-free water.
- Preferred excipients for parenteral administration include propylene glycol, ethyl oleate, pyrrolidone, ethanol, and sesame oil.
- the pharmaceutically-acceptable excipient, in compositions for parenteral administration comprises at least about 90% by weight by the total composition.
- dosages for injection may be prepared in dried or lyophilized form.
- Such forms can be reconstituted with water or saline solution, depending on the preparation of the dosage form.
- Such forms may be packaged as individual dosages or multiple dosages for easier handling.
- the reconstituted dosage form is preferably isotonic, and at a physiologically compatible pH.
- oral dosage forms can be used, including such solid forms as tablets, capsules, granules and bulk powders. These oral forms comprise a safe and effective amount, usually at least about 5%, and preferably from about 25% to about 50%, of the quinolone. Tablets can be compressed, tablet triturates, enteric-coated, sugar-coated, film-coated, or multiple-compressed, containing suitable binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, and melting agents.
- Liquid oral dosage forms include aqueous solutions, emulsions, suspensions, solutions and/or suspensions reconstituted from non- effervescent granules, and effervescent preparations reconstituted from effervescent granules, containing suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, melting agents, coloring agents and flavoring agents, such are well known to the skilled artisan.
- Preferred excipients for oral administration include gelatin, propylene glycol, cottonseed oil and sesame oil.
- compositions of this invention can also be administered topically to a subject, i.e., by the direct laying on or spreading of the composition on the epidermal or epithelial tissue of the subject.
- Such compositions include, for example, lotions, creams, solutions, gels and solids.
- These topical compositions preferably comprise a safe and effective amount, usually at least about 0.1%, and preferably from about 1% to about 5%, of the quinolone.
- Suitable excipients for topical administration preferably remain in place on the skin as a continuous film, and resist being removed by perspiration or immersion in water.
- the excipient is organic in nature and capable of having dispersed or dissolved therein the quinolone.
- the excipient may include pharmaceutically-acceptable emolients, emulsifiers, thickening agents, and solvents and the like; these are well known to the skilled artisan.
- This invention also provides methods of treating an infectious disorder in a human or other animal subject, by administering a safe and effective amount of a quinolone to said subject.
- an "infectious disorder” is any disorder characterized by the presence of a microbial infection.
- Preferred methods of this invention are for the treatment of bacterial infections.
- infectious disorders include (for example) central nervous system infections, external ear infections, infections of the middle ear (such as acute otitis media), infections of the cranial sinuses, eye infections, infections of the oral cavity (such as infections of the teeth, gums and mucosa), upper respiratory tract infections, lower respiratory tract infections, including pneumonia, genitourinary infections, gastrointestinal infections, gynecological infections, septicemia, sepsis, peritonitis, bone and joint infections, skin and skin structure infections, bacterial endocarditis, burns, antibacterial prophylaxis of surgery, and antibacterial prophylaxis in post-operative patients or in immunosuppressed patients (such as patients receiving cancer chemotherapy, or organ transplant patients).
- central nervous system infections for example, central nervous system infections, external ear infections, infections of the middle ear (such as acute otitis media), infections of the cranial sinuses, eye infections, infections of the oral cavity (such as infections of the teeth, gums and mucosa), upper respiratory tract
- treatment is used herein to mean that, at a minimum, administration of a compound of the present invention mitigates a disease associated an infectious disorder in a host, preferably in a mammalian subject, more preferably in humans.
- treatment includes: preventing an infectious disorder from occurring in a host, particularly when the host is predisposed to acquiring the disease, but has not yet been diagnosed with the disease; inhibiting the infectious disorder; and/or alleviating or reversing the infectious disorder.
- the methods of the present invention are directed to preventing infectious disorders, it is understood that the term “prevent” does not require that the disease state be completely thwarted.
- preventing refers to the ability of the skilled artisan to identify a population that is susceptible to infectious disorders, such that administration of the compounds of the present invention may occur prior to onset of infection. The term does not imply that the disease state be completely avoided.
- the quinolone derivatives and compositions of this invention can be administered topically or systemically.
- Systemic application includes any method of introducing the quinolone into the tissues of the body, e.g., intrathecal, epidural, intramuscular, transdermal, intravenous, intraperitoneal, subcutaneous, sublingual, rectal, and oral administration.
- the specific dosage of antimicrobial to be administered, as well as the duration of treatment, are mutually dependent.
- the dosage and treatment regimen will also depend upon such factors as the specific quinolone used, the resistance pattern of the infecting organism to the quinolone used, the ability of the quinolone to reach minimum inhibitory concentrations at the site of the infection, the nature and extent of other infections (if any), the personal attributes of the subject (such as weight), compliance with the treatment regimen, the age and health status of the patient, and the presence and severity of any side effects of the treatment.
- Treatment regimens preferably extend from about 1, preferably from about 3 to about 56 days, preferably to about 20 days, in duration.
- Prophylactic regimens may extend 6 months, or longer, according to good medical practice.
- a preferred method of parenteral administration is through intravenous injection.
- all formulations for parenteral administration must be sterile.
- individual doses of from about 100 mg, preferably from about 500 mg to about 7,000 mg, more preferably to about 3,500 mg, is acceptable.
- the invention may be dosed intravenously.
- the dosage form is generally isotonic and at physiological pH.
- the dosage amount will depend on the patient and severity of condition, as well as other commonly considered parameters. Determination of such doses is well within the scope of practice for the skilled practitioner using the guidance given in the specification.
- a preferred method of systemic administration is oral administration. Individual doses of from about 20 mg, more preferably from about 100 mg to about 2,500 mg, more preferably to about 500 mg.
- Topical administration can be used to deliver the quinolone systemically, or to treat a local infection.
- the amounts of quinolone to be topically administered depends upon such factors as skin sensitivity, type and location of the tissue to be treated, the composition and excipient (if any) to be administered, the particular quinolone to be administered, as well as the particular disorder to be treated and the extent to which systemic (as distinguished from local) effects are desired.
- 3-methoxy-2.4.5-trifluorobenzoyl chloride 3-Methoxy-2,4,5-difluorobenzoic acid (43.9 g, 213 mmol) is suspended in dichloromethane (30 mL) and oxalyl chloride (25 mL, 287 mmol) is added followed by 4 drops of dry DMF. The mixture is stirred at room temperature for 6 hours and the solvent is removed by evaporation to afford the desired product.
- Monoethyl malonate (26.4 g, 200 mmol) is dissolved in THF (700 mL). The solution is cooled at -50°C and n-butyllithium (160 mL 2.5 M, 400 mmol) is added, keeping the temperature below - 50°C. The temperature is initially raised to 0°C and cooled back to -50°C. 3-methoxy-2,4,5- trifluorobenzoyl chloride (20.6 g, 92 mmol) is added, keeping the temperature at -50°C, then the reaction mixture is warmed to room temperature. Hydrochloric acid is added until the pH becomes acidic. The organic phase is washed with sodium bicarbonate and dried; evaporation of the solvent affords the desired product.
- Ethyl 3-cyclopropylamino-2-(3-methoxy-2.4.5-trifluoro-benzoyl ' ) acrylate To a mixture of acetic anhydride (50 mL, 530 mmol) and triethyl orthoformate (50 mL, 300 mmol) is added ethyl 3-methoxy-2,4,5-trifluoro-benzoyl acetate (52.94 g, 192 mmol). The mixture is refluxed for 2 hours, then is cooled to room temperature. The excess reagent is removed by evaporation to provide a thick oil which is dissolved in ethanol (150 mL). Cyclopropylamine (17.2 g, 301 mmol) is then added while keeping the temperature at about 20°C. The desired product is isolated by filtration and air dried.
- Ethyl l-cyclopropyl-6.7-difluoro-1.4-dihydro-8-methoxy-4-oxo-quinoline-3-carboxylate Ethyl 3-cyclopropylamino-2-(3-methoxy-2,4,5-trifluoro-benzoyl) acrylate (30.3 g, 88 mmol) is dissolved in THF. 60% sodium hydride in oil (4.1 g, 103 mmol) is added portion-wise keeping the temperature below 40°C. The solution is stirred at room temperature for 2 hours, then poured into water. The desired product is isolated by filtration and air dried. l-Cyclopropyl-6.7-difluoro-1.4-dihydro-8-methoxy-4-oxo-quinoline-3-carboxylic acid (Precursor A)
- Ethyl-l-cyclopropyl-l,4-dihydro-6,7-difluoro-8-methoxy-4-oxo-quinoline-3-carboxylate (28.6 g, 88 mmol) is suspended in a mixture of acetic acid, water, sulfuric acid (8/6/1, 300 mL) and is refluxed for 2 hours. The reaction mixture is cooled at 0°C and the desired product is collected by filtration.
- 5-bromo-3-chloro-2,4-difluorobenzoic acid (5.2 g, 19 mmol) is suspended in dichloromethane (30 mL) and oxalyl chloride (2.92 g, 23 mmol) and dry DMF (3 drops) are added. The mixture is stirred at room temperature for 3 hours and the desired compound is isolated after evaporation of the solvent.
- Ethyl 5-bromo-2,4-difluoro-3-chloro-benzoyl acetate (6.2 g, 18 mmol) is dissolved in a mixture of acetic anhydride (4.4 mL, 47m mol) and triethyl orthoformate (4.5 mL, 27 mmol) and the mixture is heated at reflux for 2 hours. The volatiles are evaporated, the residue is dissolved in ethanol (20 mL), and the resulting solution is cooled at 0°C. Cyclopropylamine (2 mL, 29mmol) is added and, after 30 minutes, the desired product is isolated by filtration and air dried.
- Ethyl 6-bromo-8-chloro-l-cyclopropyl-1.4-dihvdro-7-fluoro-4-oxo-quinoline-3-carboxylate Ethyl 3-cyclopropylamino-2-(5-bromo-2,4-difluoro-3-chloro-benzoyl) acrylate (2.95 g, 7 mmol) is dissolved in THF (15 mL) and 60% sodium hydride (0.29 g, 7 mmol) is added portionwise. After 1 hour at room temperature, the suspension is poured into water (100 mL) and the desired product isolated by filtration and air dried.
- Ethyl 6-bromo- 1 -cyclopropyl- 1 ,4-dihydro-7-fluoro-8-chloro-4-oxo-quinoline-3 -carboxylate (1.9 g, 5 mmol) is suspended in a mixture of acetic acid, water, sulfuric acid (8/6/1, 30 mL) and is refluxed for 2 hours. The reaction mixture is cooled to room temperature and poured into cold water (50 mL). The precipitate is collected by filtration, washed with water, and air dried.
- Ethyl 6-Bromo-8-chloro-l-cyclopropyl-7-fluoro-l,4-dihydro-4-oxoquinoline-3-carboxyate (0.5 g, 1.3 mmol), lithium chloride (0.165 g, 3.9 mmol), tris(dihenzylideneacetone)dipalladium (0.120 g, 0.13 mmol), tetramethyltin (0.465 g, 2.6 mmol) and 2,6-di-tert-butyl-4-methyl-phenol (BHT, 25 mg) are combined in DMF (40 mL) and heated at 70-75°C for 18 hours. The solvent is then removed in vacuo. The residue is triturated with hexanes and then purified by flash chromatography on silica gel using
- 3-Chloro-2,4-difluorobenzoic acid (10 g, 52 mmol) is added to a mixture of fuming nitric acid (10 mL) and sulfuric acid (13 mL) at 0°C. The suspension is then stirred at room temperature for 30 minutes and poured onto ice. Filtration of the resulting solid affords the desired product.
- Ethyl 5-nitro-3-chloro-2,4-difluoro-benzoyl acetate (4.10 g, 13.3 mmol) is dissolved in a mixture of triethyl orthoformate (3.4 mL, 20 mmol) and acetic anhydride (6 mL, 64 mmol). The reaction mixture is warmed at 120°C for 3 hours and the remaining volatiles are removed under vacuum. The residue is dissolved in ethanol (15 mL) and the solution is cooled at -5° C.
- Ethyl 3-cyclopropylamino-2-(2,4-difluoro-3-chloro-5-nitro-benzoyl) acrylate (3.41 g, 9.1 mmol) is dissolved in EtOAc (40 mL) at 0°C .
- Potassium carbonate (3.9 g, 28 mmol) is added and the reaction mixture is stirred at 0°C for 2 hours.
- the mixture is poured into ice water and the desired product is isolated by filtration, washed with water, and air dried.
- 2,6-dichloro-5-fluoro-3-nicotinic acid (4 g, 19 mmol) is suspended in CH 2 C1 2 and oxalyl chloride (2.72 g, 21 mmol) is added followed by 3 drops of DMF. The mixture is allowed to stir for 3 hours at room temperature and the solvent is evaporated to afford the desired product.
- Ethyl-3-(2,6-dichloro-5-fluoropyridinyl)-3-oxo-2-carboxyethyl propanoate (6 g, 17 mmol) is mixed with water (30 mL) and p-toluenesulfonic acid monohydrate (0.15 g, 0.8 mmol) and heated at 100°C for one hour. After cooling to room temperature the aqueous solution is extracted with ethyl acetate and the combined organic layers are dried over Na 2 S0 . The spent dessicant is removed by filtration and the filtrate concentrated to give the desired product.
- Ethyl-3-(2,6-dichloro-5-fluoropyridinyl)-3-oxo-propanoate (5 g, 18 mmol) is mixed with triethyl orthof ornate (4.3 mL, 26 mmol) and acetic anhydride (4.1 mL, 43 mmol) and the mixture is heated at reflux for 2 hours. The mixture is then concentrated under vacuum to afford the desired product.
- Ethyl-3-(2.6-dichloro-5-fluoropyridinylV3-oxo-2-cyclopropylaminomethylene-propanoate Ethyl-3-(2,6-dichloro-5-fluoropyridinyl)-3-oxo-2-ethoxymethylene-propanoate (2.65 g, 8 mmol) is dissolved in ethanol (5 mL) and the solution is cooled at 0°C. Cyclopropylamme (0.8 mL, 12 mmol) is added progressively and the mixture is allowed to stir at room temperature for one hour. The desired product is obtained after evaporation of the volatiles.
- Ethyl-3-(2,6-dichloro-5-fluoropyridinyl)-3-oxo-2-cyclopropylaminomethylene-propanoate (1.09 g, 3 mmol) is dissolved in acetonitrile (15 mL) and potassium carbonate (840 mg, 6 mmol) is added. The mixture is heated at reflux for 18 hours and poured into water. The precipitate is filtered and purified by flash chromatography using 2% methanol in CH 2 CL*>.
- Ethyl hydrogen malonate (26.4 g, 200 mmol) is dissolved in THF (700 mL) and the solution is cooled at -35°C.
- n-BuLi 160 mL, 2.5 M in hexane, 400 mmol
- a solution of 2,3,4,5-tetrafluorobenzoyl chloride (21.1 g, 100 mmol) in THF (10 mL) is added and then the reaction is allowed to warm to room temperature.
- the solution is poured in IN HCI and extracted with ether.
- the extracts are washed with a bicarbonate solution, brine and dried over Na 2 S0 .
- the desired product is purified by flash chromatography on silica gel using 15% EtOAc in hexanes.
- Ethyl-3-(2,3,4,5-tetrafluorophenyl)-3-oxo-propanoate (10 g. 38 mmol) is dissolved in a mixture of triethyl orthoformate (10 mL, 60 mmol) and acetic anhydride (10 mL, 106 mmol) and the solution is heated at reflux for 3 hours. After concentration under vacuum, the residue is dissolved in CH 2 C1 2 and cooled at 0° C. 2S-aminopropanol (4.26 g, 55mmol) is added dropwise and the solution is allowed to warm to room temperature. The product is purified by flash chromatography on silica gel using 25% EtOAc in hexanes.
- Ethyl-3-(2,3,4,5-tetrafluorophenyl)-3-oxo-2-[3-amino-2S-methyl-propanol-3-yl]-methylene- propanoate (9.78 g, 28 mmol) is dissolved in DMF (25 mL) and 60% sodium hydride in oil (1.17 g, 29 mmol) is added. After 20 minutes at room temperature, the solution is heated overnight. The solvent is removed under vacuum and the residue is triturated with hexanes and treated with water. The desired product is obtained by filtration.
- Ethyl-9,10-difluoro-2,3-dihydro-3S-methyl-7-oxo-7H-pyrido[l,2,3-de]-l,4-benzoxazine-6- carboxylate (8.2 g, 27 mmol) is dissolved in THF and 10% aqueous KOH (25 mL) is added. The solution is heated at 65 °C for 2 hours. The THF is evaporated and the pH is adjusted to 3 by addition of acetic acid. The desired product is obtained by filtration.
- Phenyl N-cyclopropyliminomercaptothioformate iV-Cyclopropyl isothiocyanate (5 g, 50 mmol) and thiophenol (5.2 mL, 51 mmol) are mixed together at 0°C. After stirring 30 minutes at 0°C, two drops of triethylamine are added to initiate the reaction. The mixture immediately becomes yellow and slowly solidifies. The white solid is broken apart, collected on a filter, and washed with hexanes to give the desired product.
- Phenyl N-cvclopropyliminochlorothioformate Phosphorus pentachloride (10.5 g, 50 mmol) is added to phenyl N- cyclopropyliminomercaptothioformate, the flask is equipped with a reflux condenser, and the solid mixture is heated at 65 °C under argon. The solids slowly melt to become a yellow solution. The mixture is allowed to stir 6 hr at 65°C, then is cooled to room temperature. The flask is equipped with a distillation apparatus and the desired product is distilled.
- Ethyl hydrogen malonate (33.69 g, 255 mmol) is dissolved in dry THF (640 mL). The mixture is cooled to -78°C and n-butyllithium (319 mL, 1.6 M in hexanes, 510 mmol) is added at a rapid drop rate such that the internal temperature remains below -30°C. The cooling bath is then removed and the mixture is allowed to warm to -20°C. The reaction is re-cooled to -78°C and 2,3,4,5 ,6-pentafluorobenzoyl chloride (25 g, 108 mmol) is added in dry THF (40 mL) via cannula. The yellow solution is allowed to warm to room temperature and stir overnight.
- reaction mixture is poured into a vigorously stirring solution of dilute HCI (125 mL) and allowed to stir 1 hour, before the layers are separated and the aqueous layer is extracted with ether.
- the organic phase is washed with saturated aqueous sodium bicarbonate solution and brine and dried over MgS04. After concentrating, the desired product is distilled under reduced pressure (5 mm Hg).
- the resulting mixture is heated at 50°C for 4 hours, then at reflux for 20 hours before being cooled to room temperature and diluted with CH 2 C1 2 .
- the organic layer is washed once with water, dried over MgS ⁇ 4, and concentrated to give a dark oil which is purified by flash chromatography on silica gel using 15% acetone in hexanes.
- Ethyl l-cyclopropyl-2-phenylsulfinyl-5,6,7,8-tetrafluoro-l,4-dihydro-4-oxoquinoline-3- carboxylate (0.225 g, 0.496 mmol) is dissolved in THF (15 L) and the solution is cooled at 0°C.
- Sodium hydrosulfite 60 mg
- dissolved in water (2 mL) is then added followed by a solution of sodium bicarbonate (0.5 g in 10 mL).
- the solution is stirred at 0°C for one hour and hydroxylamine-0-sulfonic acid (0.264 g, 2.3 mmol) is added.
- the solution is allowed to warm at room temperature and after 3 hours is treated with dilute hydrochloric acid.
- the crude desired product is collected by filtration and purified by crystallization from ethanol.
- 3-Chloro-2,4,5,6-tetrafluoropyridine (50.0 g, 270 mmol) is dissolved in dry THF (500 mL) and cooled to 0°C.
- a solution of lithium tert-butoxide (270 mL, 1.0 M in THF, 270 mmol) is added dropwise over 50 minutes and the solution is then allowed to stir an additional 90 min. at 0°C before warming to room temperature.
- the reaction mixture is poured into hexanes (1000 mL) and filtered through a pad of Celite®. After concentration via rotary evaporation, the liquid purified by flash chromatography on silica gel using hexanes to isolate the desired compound.
- Methyl iodide (9.45 mL, 152 mmol) is added via syringe and the cooling bath is removed. After stirring 90 minutes, the slurry is poured into a saturated aqueous ammonium chloride solution (250 mL) and is extracted twice with hexanes. The combined organic layers are washed with water and brine and dried over MgS04. Evaporation of the solvent provides the desired compound.
- the mixture is allowed to stir 1 hour at -78°C and 1 hour at room temperature before it is poured into a saturated aqueous ammonium chloride solution (150 mL) and extracted twice with ether. The combined organic layers are washed with brine, dried over MgS ⁇ 4, and concentrated to give a yellow oil. The oil is purified by flash chromatography on silica gel using 20% EtOAc in hexanes to give the desired product.
- Hydrogen chloride gas is bubbled through a solution of 2-(4-chloro-5-fluoro-3-methyl-2- pyridinyl)cyclopropaneacetonitrile (2.91 g, 13 mmol) in ethanol (9 mL) until the weight increases by 3.56 g and then the mixture is heated to boiling. Water (0.32 mL) is added and the mixture is allowed to heat at reflux for 2 hours before cooling it to room temperature and adding more water. The pH is adjusted to 7 with solid sodium bicarbonate and it is extracted with CH 2 C1 2 . The combined organic layers are washed with water, dried over MgS ⁇ 4, and concentrated to give a yellow liquid which is purified by flash chromatography on silica gel using 20% EtOAc in hexanes to give the desired product.
- 2,4,6-Trifluoropyridine (16.6 g, 125 mmol) is added to a mixture of 35 ml of fuming nitric acid and 45 ml of sulfuric acid at 0°C. The suspension is then stirred at room temperature for 30 minutes and poured onto ice. Filtration affords the desired product.
- 3-Nitro-2,4,6-trifluoropyridine (19.6 g, 110 mmol) is dissolved in dry THF (250 mL) and cooled at 0°C.
- a solution of lithium tert-butoxide (135 mL, 1.0 M in THF, 110 mmol) is added dropwise over 50 minutes and the solution is then stirred an additional 90 min. at 0°C before warming to room temperature.
- the reaction mixture is poured into hexanes (500 mL) and filtered through a pad of Celite®. After concentration via rotary evaporation, the liquid is purified by flash chromatography on silica gel using 5% ether in hexanes to isolate the desired compound.
- aqueous solution is extracted with hexanes (3 x) and the combined organic layers are washed with water and brine, dried over MgS0 4 , and concentrated. Purification by flash chromatography using EtOAc/hexanes gives the desired product.
- Tris(dibenzylideneacetone)dipalladium (21.1 g, 23.1 mmol), tti-o-tolylphosphine (28.1 g, 91.7 mmol), cuprous chloride (4.55 g, 45.5 mmol), and potassium carbonate (6.35 g, 45.5 mmol) are placed under argon.
- the mixture is stirred 1 hour at -78°C and 1 hour at room temperature and then is poured into a saturated aqueous ammonium chloride solution (85 mL) and extracted twice with ether. The combined organic layers are washed with brine, dried over MgS ⁇ 4, and concentrated to give a yellow oil.
- the oil is purified by flash chromatography on silica gel using 20% ethyl acetate in hexanes to give the desired product.
- the aqueous layer is extracted twice more with CH 2 C1 2 and the combined organic layers are washed once with water, dried over MgS0 4 , and concentrated.
- the desired product is purified by flash chromatography using 20% ethyl acetate in hexanes.
- Hydrogen chloride gas (2.02 g, 55 mmol) is bubbled through a solution of 2-(4-chloro-5-nitro-3- methyl-2-pyridinyl)cyclopropaneacetonitrile (1.85 g, 7.4 mmol) in ethanol (5 mL) and the resulting mixture is heated to boiling. Water (0.18 mL) is added and heating is continued at reflux for 2 h before cooling the mixture to room temperature and adding water. The pH is adjusted to 7 with solid sodium bicarbonate and the aqueous solution is extracted with CH 2 C1 2 .
- the solvents are removed and the residue is dissolved in ether.
- the ether layer is washed with water and brine, dried over MgS04 and concentrated.
- the desired product is purified by flash chromatography on silica gel using 20% ethyl acetate in hexanes.
- reaction mixture is diluted with CH 2 C1 2 and washed with saturated NaHC0 3 , water, and brine.
- the organic layer is dried over MgS0 and filtered.
- the filtrate is concentrated under vacuum and purified by flash chromatography using 33% EtOAc in hexanes to give the desired product.
- Tris(dibenzylideneacetone)dipalladium (3.29 g, 3.6 mmol), tri-o-tolylphosphine (4.38 g, 14.3 mmol), cuprous chloride (0.71 g, 7.1 mmol), and potassium carbonate (0.99 g, 7.1 mmol) are placed under argon.
- 4,5-Difluoro-3-methyl-2-nitrobenzoic acid ethyl ester (1.26 g, 5.1 mmol) is combined with ethanol (20 mL) and 10% Pd/C catalyst (0.13 g) and the mixture is shaken under hydrogen (40 psi) for 6 hours at room temperature. The catalyst is removed by filtration through Celite and the solvent is evaporated to give the desired product.
- the dry solid is added to a solution of triethylamine (1.13 mL, 8.1 mmol) in THF (50 mL) and the mixture is heated at reflux overnight.
- the reaction mixture is cooled, the solvent is removed under reduced pressure, and the residue is dissolved in water (22.5 mL) which is then acidified to pH 1-2 with 1 M HCI.
- the resulting precipitate is collected by filtration.
- DIBAL diisobutylaluminum hydride
- a suspension of L-glutamic acid (18.0 g, 122 mmol) in methanol (120 mL) is cooled in a ice bath.
- the mixture is treated dropwise with thionyl cholride (12.45 mL, 171 mmol) and the mixture is allowed to stir at room temperature for 18 hours.
- the reaction is concentrated, toluene is added to the residue, and the volatiles are removed by evaporation. This process is repeated twice more to give the desired product.
- a solution of lithium hexamethyldisilylazide (152.6 mL, IM in THF, 152.6 mmol) is cooled under argon in a dry ice/acetone bath.
- a solution of 2(S)-tert-butoxycarbonylamino-pentanedioic acid dimethyl ester (20 g, 72.6 mol) in THF (200 mL) is added via cannula, maintaining the temperature below -60 °C.
- After 30 minutes at -78°C methyl iodide (9 mL, 145 mmol) is added as rapidly as possible via cannula.
- the reaction mixture is stirred -78°C for 4.5 hour and then quenched with 1 N HCI (190 mL).
- the reaction mixture is stirred for 1 hour and is then quenched with 1 N HCI (10 mL).
- the aqueous layer is extracted EtOAc (3 x 5 mL) and the combined extracts are washed with brine and dried over Na 2 S0 .
- the spent dessicant is removed by filtration and the volatiles evaporated under reduced pressure to leave an oil which is purified by chromatography using 15 to 25 % EtOAc/hexanes.
- the filtrate is concentrated in vacuo to yield a cloudy oil.
- the crude product is purified by flash chromatography on silica gel using 0-5% ether in hexanes to give the desired product.
- the excess 2(S)-tert-butoxycarbonylamino-N-(l-prop-2-ynyl)-but-3-enylamine is recovered by basifying an aqueous solution of the filtered salt with NaOH (2 M) followed by Et 2 0 extraction and concentration.
- reaction mixture is quenched with water and the ether layer is separated, washed with 10% HCI, water, and NaHC0 3 , and dried over K 2 C0 3 . Removal of the spent dessicant and concentration gives an oil which is purified by flash chromatography on silica gel using 10% EtOAc in hexanes.
- the filtrate is concentrated in vacuo to yield a cloudy oil.
- the crude product is purified by flash chromatography on silica gel using 0-5% ether in hexanes to give the desired product.
- the excess 2(S)-tert-butoxycarbonylamino-N-(l-methyl-2-propenyl)-but-3-enylamine is recovered by basifying an aqueous solution of the filtered salt with NaOH (2 M) followed by Et 2 0 extraction and concentration.
- the yellow solution is warmed to room temperature over 2 hours and stirred for another 2 hours.
- Methanol (0.8 mL) is added to the resultant dark-brown solution; the color immediately changes to yellow.
- the mixture is diluted with saturated NaHC0 3 solution (10 mL) and Et 2 0 (20 mL), the layers separated, and the aqueous layer extracted with Et 2 0 (3 x 50 mL).
- the combined organic extracts are dried (K 2 C0 3 ) and concentrated in vacuo to yield a cloudy yellow oil.
- the crude product is purified by flash chromatography on silica gel using 3% triethylamine in hexanes to give the major diastereomer as the desired product.
- 3(S)-tert-butoxycarbonylamino-4(R)-methyl-5.5-dimethyl-piperidine (Precursor R) 3(S)-tert-butoxycarbonylamino-4(R)-methyl-5,5-dimethyl-l-benzyl-piperidine (0.69 g, 2.1 mmol) is combined with 10% Pd/C (0.07 g) in methanol (25 mL) and is shaken under a hydrogen atmosphere (40 psi) at room temperature for 15 h. The spent catalyst is removed by filtration through Celite and the solvent is removed in vacuo to give the desired product.
- the crude product is purified by flash chromatography on silica gel using 0-5% ether in hexanes to give the desired product.
- the excess 2(S)-tert-butoxycarbonylamino-N-(l-methyl-2-propenyl)-but-3-enylamine is recovered by basifying an aqueous solution of the filtered salt with NaOH (2 M) followed by Et 2 0 extraction and concentration.
- the yellow solution is warmed to room temperature over 2 hours and stirred for another 2 hours.
- Methanol 0.5 mL is added to the resultant dark-brown solution; the color immediately changes to yellow.
- the mixture is diluted with saturated NaHC0 3 solution (7 mL) and Et 2 0 (15 mL), the layers separated, and the aqueous layer extracted with Et 2 0 (3 x 35 mL).
- the combined organic extracts are dried (K 2 C0 3 ) and concentrated in vacuo to yield a cloudy yellow oil.
- the crude product is purified by flash chromatography on silica gel using 3% triethylamine in hexanes to give the major diastereomer as the desired product.
- Example 1 7-[3S-amino-5S-methyl-piperidinyl]-l-cyclopropyl-l,4-dihydro-6-fluoro-8-methoxy-4-oxo-3- quinolinecarboxylic acid hydrochloride l-cyclopropyl-l,4-dihydro-6,7-difluoro-8-methoxy-4-oxo-quinoline-3-carboxylic acid
- Precursor A (0.059 g, 0.200 mmol), (5(S)-methyl-piperidin-3(S)-yl)-carbamic acid tert-butyl ester (Precursor M)_(0.048 g, 0.210 mmol) and triethylamine (0.075 mL) are dissolved in N- methyl-pyrrolidone (2 mL).
- the reaction mixture is stirred at 80°C for 5 hours, then is poured on an ice/water mixture. The pH is lowered to 2 with diluted HCI and the resulting precipitate is filtered. The solid is then suspended in ethanol and 6N HCI is added. After 18 hours at room temperature, the desired final product is collected by filtration.
- Example 1 A procedure similar to Example 1 above is used, but using 1 -cyclopropyl- l,4-dihydro-6,7- difluoro-8-methoxy-4-oxo-quinoline-3-carboxylic acid (Precursor A) and (5,5-dimethyl- piperidin-3(S)-yl)-carbamic acid tert-butyl ester (Precursor O) as the starting materials.
- the procedure utilizes the same reaction conditions and molar ratio of reactants as Example 1.
- Example 7 7-[3S-amino-5S-methyl-piperidinyl]-6-bromo-8-chloro-l-cyclopropyl-l,4-dihydr ⁇ "4-oxo-3- quinolinecarboxylic acid dihydrochloride
- Example 8 7-[3S-amino-4R-ethyl-5S-methyl-piperidinyl]-6-bromo-8-chloro-l-cyclopropyl-l,4-dihydro- -4-oxo-3-quinolinecarboxylic acid hydrochloride
- Precursor C (lg, 3.4 mmol) is dissolved in THF (10 L) and boron trifluoride etherate (1.76 mL, 13.9 mmol) is added. The mixture is stirred at 60°C for 2 hours then cooled to room temperature. The desired product is collected by filtration, washed, and air dried.
- Precursor D (0.064 g, 0.180 mmol) and 3(S)-tert-butoxycarbonylamino-4(R)-methyl-5(S)- methyl-piperidine (Precursor S) (0.08 g, 0.351 mmol) are dissolved in DMSO (1 mL) and stirred at room temperature for 15 minutes. Water (5 mL) is then added and the desired product collected by filtration.
- Ethyl 7-[3S-t-butoxycarbonylamino-4R-methyl-5S-methyl-piperidinyl]-8-chloro-l-cyclopropyl- l,4-dihydro-6-nitto-4-oxo-3-quinolinecarboxylate (0.072 g, 0.128 mmol) is dissolved in ethanol (1 mL) and Raney Nickel (0.035 g) is added. The reaction mixture is stirred under hydrogen (1 atm) at room temperature for 18 hours. The catalyst is removed by filtration on Celite and the filtrate evaporated to give the desired product.
- the resulting solid is collected by filtration and suspended in a 1/1 mixture of 2N NaOH and ethanol (1 mL) and stirred at room temperature for 24 hours.
- the pH is then adjusted to 7.4 using IN HCI and the precipitate is collected by filttation.
- the solid is resuspended in ethanol and tteated with 6N hydrochloric acid for 18 hr at room temperature.
- the desired final product is collected by filtration.
- Example 13 7-[3S-amino-5S-methyl-piperidinyl]-9-fluoro-2,3-dihydro-3S-methyl-7-oxo-7H-pyrido[l,2,3- de]-l,4-benzoxazine-6-carboxylic acid hydrochloride.
- Example 14 7-[3S-amino-5,5-dimethyl-piperidinyl]-9-fluoro-2,3-dihydro-3S-methyl-7-oxo-7H- pyrido[l,2,3-de]-l,4-benzoxazine-6-carboxylic acid hydrochloride.
- Precursor G (0.067 g, 0.203 mmol) is suspended in DMF (1 L) and (8(R)-methyl-5-aza- spiro[2.5]oct-7-yl)-carbamic acid tert-butyl ester (Precursor Q) (0.051 g, 0.212 mmol) and triethylamine (0.05, 0.359 mmol mL) is added.
- the reaction mixture is stirred at 50°C for 6 hr.
- the mixture is concentrated under vacuum, and the residue is triturated with water.
- the precipitate is collected, rinsed with ethanol, and suspended in ethanol. Drops of 12N HCI are added and the suspension is stirred for 12 hr at 20°C.
- the desired product is collected by filtration and air dried.
- Example 15 A procedure similar to Example 15 above is used using 5,6,7,8-tetrafluoro-9-cyclopropyl-l,3,4,9- tetrahydroisothiazolo[5,4-b]quinoline-3,4-dione (Precursor G) and (5(S)-ethyl-piperidin-3(S)- yl)-carbamic acid tert-butyl ester (Precursor N) as the starting materials.
- the procedure utilizes the same reaction conditions and molar ratio of reactants as Example 15.
- Example 17 A procedure similar to Example 17 above is used, using ethyl 8-chloro-l-cyclopropyl-7-fluoro-9- methyl-4-oxo-4H-quinolizine-3-carboxylate (Precursor H) and (5(S)-ethyl-piperidin-3(S)-yl)- carbamic acid tert-butyl ester (Precursor N) as the starting materials.
- the procedure utilizes the same reaction conditions and molar ratio of reactants as Example 17.
- Ethyl 8-[3S-t-butoxycarbonylamino-5S-ethyl-piperidinyl]-7-amino-l-cyclopropyl-9-methyl-4- oxo-4H-quinolizine-3-carboxylate (0.062 g, 0.120 mmol) is dissolved in 2N HCI (2 mL) at 0°C. A solution of sodium nitrite (0.009 g, 0.130 mmol) in water (0.2 mL) is then added and the solution stirred at 0°C for 1 hour. A solution of NaBF 4 (0.02 g, 0.182 mmol) in water (0.2 mL) is added and the resulting precipitate filtered.
- reaction mixture After cooling to room temperature, the reaction mixture is diluted with ethyl acetate and washed with saturated NaHC0 3 , water, and brine. The organic layer is dried over MgS0 4 , filtered, and concentrated. The resulting residue is purified by flash chromatography on silica gel using EtOAc/hexanes to give the desired product.
- Hydrogen chloride gas is bubbled into CH 2 C1 2 for 15 minutes.
- the resulting solution is then cooled to 0°C and added to a solution of ⁇ 7-[3S-amino-5S-methyl-piperidin-l-yl)-8-chloro-l- cyclopropyl-6-fluoro-2,4-dioxo-l,4-dihydro-2H-quinazolin-3-yl ⁇ carbamic acid tert-butyl ester (0.067 g, 0.115 mmol).
- the resulting mixture is slowly warmed to room temperature. After 30 hours, the precipitate is filtered, washed with CH 2 C1 2 and hexanes, and dried under vacuum to give the desired product.
- Example 20 A procedure similar to Example 20 above is used, using 8-chloro-l-cyclopropyl-6,7-difluoro-2,4- dioxo-l,4-dihydro-2H-quinazolin-3-yl)carbamic acid tert-butyl ester (Presursor J) and 3(S)-tert- butoxycarbonylamino-4(R)-ethyl-5(S)-methyl-piperidine (Precursor L) as the starting materials.
- the procedure utilizes the same reaction conditions and molar ratio of reactants as Example 20.
- Hydrogen chloride gas is bubbled into CH C1 2 for 15 minutes.
- the resulting solution is then cooled to 0°C and added to a solution of 7-[3S-t-butoxycarbonylamino-5S-methyl-piperidinyl)-3- amino-l-cyclopropyl-6-fluoro-8-methyl-lH-quinazoline-2,4-dione (0.070 g, 0.145 mmol).
- the resulting mixture is slowly warmed to room temperature. After 30 hours, the precipitate is filtered, washed with CH 2 C1 2 and hexanes, and dried under vacuum to give the desired product.
- Example 22 A procedure similar to Example 22 above is used, using 3-amino-l-cyclopropyl-6,7-difluoro-8- methyl-lH-quinazoline-2,4-dione (Presursor K) and 3(S)-tert-butoxycarbonylamino-4(R)- methyl-5,5-dimethyl-piperidine (Precursor R) as the starting materials.
- the procedure utilizes the same reaction conditions and molar ratio of reactants as Example 22.
- a tablet composition for oral administration is made comprising:
- a capsule containing 200 mg of active for oral administration is made comprising:
- Component Amount (%w/w)
- a saline-based composition for ocular administration is made comprising:
- Component Amount (%w/w)
- An intranasal composition for local administration is made comprising:
- Component Composition (% w/v
- Example 20 An inhalation aerosol composition, according to the present invention, is made comprising:
- Component Composition (% w/v)
- Example 21 A topical opthalmic composition, according to the present invention, is made comprising:
- Component Composition (% w/v)
- Example 22 An antimicrobial composition for parenteral administration, according to this invention, is made comprising:
- the above ingredients are mixed, fo ⁇ ning a suspension.
- Approximately 2.0 mL of the suspension is systemically administered, via intramuscular injection, to a human subject suffering from a lower respiratory tract infection, with Streptococcus pneumoniae present. This dosage is repeated twice daily, for approximately 14 days. After 4 days, symptoms of the disease subside, indicating that the pathogen has been substantially eradicated.
- Other compounds having a structure according to Formula (I) are used with substantially similar results.
- Example 23 An enteric coated antimicrobial composition for oral administration, according to this invention, is made comprising the following core tablet:
- the components are admixed into a bulk mixture.
- Compressed tablets are formed, using tabletting methods known in the art.
- the tablet is then coated with a suspension of methacrylic acid/methacrylic acid ester polymer in isopropanol/acetone.
- a human subject having a urinary tract infection with Escherichia coli present, is orally administered two of the tablets, every 8 hours, for 4 days. Symptoms of the disease then subside, indicating substantial eradication of the pathogen.
- Other compounds having a structure according to Formula (I) are used with substantially similar results.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003259169A AU2003259169A1 (en) | 2002-07-31 | 2003-07-18 | Antimicrobial aza-bicyclic derivatives, their compositions and uses |
JP2004527622A JP2005536532A (en) | 2002-07-31 | 2003-07-18 | Antimicrobial aza-bicyclic derivatives, compositions thereof and uses thereof |
CA002493146A CA2493146A1 (en) | 2002-07-31 | 2003-07-18 | Antimicrobial aza-bicyclic derivates, their compositions and uses |
IL16604103A IL166041A0 (en) | 2002-07-31 | 2003-07-18 | Antimicrobial quinolones their compositions and uses |
MXPA05001180A MXPA05001180A (en) | 2002-07-31 | 2003-07-18 | Antimicrobial aza-bicyclic derivates, their compositions and uses. |
NZ537203A NZ537203A (en) | 2002-07-31 | 2003-07-18 | Antimicrobial quinolones, their compositions and uses |
BR0313420-2A BR0313420A (en) | 2002-07-31 | 2003-07-18 | Microbicidal Quinolones, their compositions and uses |
EP03784784A EP1532137A2 (en) | 2002-07-31 | 2003-07-18 | Antimicrobial aza-bicyclic derivates, their compositions and uses |
NO20051082A NO20051082L (en) | 2002-07-31 | 2005-02-28 | Antimicrobial quinolones, their compositions and applications |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40001402P | 2002-07-31 | 2002-07-31 | |
US60/400,014 | 2002-07-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004014893A2 true WO2004014893A2 (en) | 2004-02-19 |
WO2004014893A3 WO2004014893A3 (en) | 2004-04-08 |
Family
ID=31715691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/022587 WO2004014893A2 (en) | 2002-07-31 | 2003-07-18 | Antimicrobial aza-bicyclic derivates, their compositions and uses |
Country Status (17)
Country | Link |
---|---|
US (1) | US6900224B2 (en) |
EP (1) | EP1532137A2 (en) |
JP (1) | JP2005536532A (en) |
KR (1) | KR20050026074A (en) |
CN (1) | CN1671690A (en) |
AU (1) | AU2003259169A1 (en) |
BR (1) | BR0313420A (en) |
CA (1) | CA2493146A1 (en) |
IL (1) | IL166041A0 (en) |
MA (1) | MA27467A1 (en) |
MX (1) | MXPA05001180A (en) |
NO (1) | NO20051082L (en) |
NZ (1) | NZ537203A (en) |
PL (1) | PL375388A1 (en) |
RU (1) | RU2005105337A (en) |
WO (1) | WO2004014893A2 (en) |
ZA (1) | ZA200500877B (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7141565B1 (en) | 2003-04-07 | 2006-11-28 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs |
US7163948B2 (en) | 2003-04-07 | 2007-01-16 | Cylene Pharmaceuticals, Inc. | Heterocyclic substituted 1,4-dihydri-4ox9-1,8-naphthyridine analogs |
WO2007110836A1 (en) * | 2006-03-28 | 2007-10-04 | The Procter & Gamble Company | A hydride reduction process for preparing quinolone intermediates |
US7354916B2 (en) | 2003-04-07 | 2008-04-08 | Cylene Pharmaceuticals | Substituted quinobenzoxazine analogs |
US7456279B2 (en) | 2006-03-28 | 2008-11-25 | The Procter & Gamble Company | Coupling process for preparing quinolone intermediates |
US7507727B2 (en) | 2003-04-07 | 2009-03-24 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs and methods of using thereof |
WO2009046383A1 (en) * | 2007-10-05 | 2009-04-09 | Cylene Pharmaceuticals, Inc. | Quinolone analogs and methods related thereto |
US7652134B2 (en) | 2004-09-17 | 2010-01-26 | Cylene Pharmaceuticals, Inc. | Methods for converting quinolone esters into quinolone amides |
US7723355B2 (en) * | 2006-11-20 | 2010-05-25 | Bristol-Myers Squibb Company | 7,8-dihydro-1,6-naphthyridin-5(6H)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase IV and methods |
WO2010077798A2 (en) | 2008-12-15 | 2010-07-08 | Taigen Biotechnology Co., Ltd. | Stereoselective synthesis of piperidine derivatives |
US7816406B2 (en) | 2004-09-17 | 2010-10-19 | Cylene Pharmaceuticals, Inc. | Quinolone analogs |
US8039485B2 (en) | 2006-03-28 | 2011-10-18 | Warner Chilcott Company, Llc | Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid |
US9957282B2 (en) | 2015-12-14 | 2018-05-01 | Senhwa Biosciences, Inc. | Crystalline forms of quinolone analogs and their salts |
WO2019206798A1 (en) * | 2018-04-25 | 2019-10-31 | Bayer Animal Health Gmbh | Process for the hydrolysis of quinolone carboxylic esters |
US10857156B2 (en) | 2015-11-20 | 2020-12-08 | Senhwa Biosciences, Inc. | Combination therapy of tetracyclic quinolone analogs for treating cancer |
US11524012B1 (en) | 2018-02-15 | 2022-12-13 | Senhwa Biosciences, Inc. | Quinolone analogs and their salts, compositions, and method for their use |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999014214A1 (en) * | 1997-09-15 | 1999-03-25 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
HU228233B1 (en) * | 1999-12-28 | 2013-02-28 | Teikoku Seiyaku Co | Antipruritic agents for external use |
US8658183B2 (en) * | 2007-08-09 | 2014-02-25 | Taigen Biotechnology Company, Ltd. | Antimicrobial parenteral formulation |
TR201820964T4 (en) * | 2008-07-01 | 2019-01-21 | Taigen Biotechnology Co Ltd | Treatment of antibiotic resistant bacterial infection. |
CN101618039B (en) * | 2008-07-02 | 2012-04-11 | 太景生物科技股份有限公司 | Pneumonia treatment |
FR2936798B1 (en) * | 2008-10-03 | 2012-09-28 | Novexel | NOVEL HETEROCYCLIC NITROGEN COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIAL MEDICINES. |
FR2936951B1 (en) * | 2008-10-10 | 2010-12-03 | Novexel | NOVEL COMBINATIONS OF ANTIBACTERIAL NITROGENIC HETEROCYCLIC COMPOUNDS WITH OTHER ANTIBACTERIAL COMPOUNDS AND THEIR USE AS MEDICAMENTS |
FR2937034B1 (en) * | 2008-10-10 | 2012-11-23 | Novexel | NOVEL HETEROCYCLIC NITROGEN COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIAL MEDICINES |
CN102093260B (en) * | 2009-12-14 | 2014-03-05 | 太景生物科技股份有限公司 | Stereospecific synthesis of piperidine derivative |
WO2017112719A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor |
WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
WO2018112840A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of m4 muscarinic acetylcholine receptor |
WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5-(pyridin-3-yl)oxazole allosteric modulators of m4 muscarinic acetylcholine receptor |
WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 3-(1h-pyrazol-4-yl)pyridine allosteric modulators of m4 muscarinic acetylcholine receptor |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0342675A2 (en) * | 1988-05-19 | 1989-11-23 | Chugai Seiyaku Kabushiki Kaisha | Novel quinolonecarboxylic acid derivatives |
WO1999014214A1 (en) * | 1997-09-15 | 1999-03-25 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
US20020049192A1 (en) * | 1997-09-15 | 2002-04-25 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
WO2002048138A1 (en) * | 2000-12-14 | 2002-06-20 | The Procter & Gamble Company | Antimicrobial quinolones |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995010519A1 (en) * | 1993-10-14 | 1995-04-20 | Abbott Laboratories | Quinolizinone type compounds |
CA2222322A1 (en) * | 1995-06-06 | 1996-12-12 | Abbott Laboratories | Quinolizinone type compounds |
KR100241673B1 (en) * | 1997-08-09 | 2000-03-02 | 김충섭 | Quinolizine Carboxylic acid Derivatives |
GB9822440D0 (en) | 1998-10-14 | 1998-12-09 | Smithkline Beecham Plc | Medicaments |
GB9914486D0 (en) | 1999-06-21 | 1999-08-18 | Smithkline Beecham Plc | Medicaments |
US7094780B1 (en) * | 2000-01-24 | 2006-08-22 | Warner Lambert Company Llc | 3-aminoquinazolin-2,4-dione antibacterial agents |
-
2003
- 2003-06-16 US US10/462,554 patent/US6900224B2/en not_active Expired - Fee Related
- 2003-07-18 CN CNA038183137A patent/CN1671690A/en active Pending
- 2003-07-18 MX MXPA05001180A patent/MXPA05001180A/en not_active Application Discontinuation
- 2003-07-18 KR KR1020057001728A patent/KR20050026074A/en active IP Right Grant
- 2003-07-18 CA CA002493146A patent/CA2493146A1/en not_active Abandoned
- 2003-07-18 IL IL16604103A patent/IL166041A0/en unknown
- 2003-07-18 EP EP03784784A patent/EP1532137A2/en not_active Withdrawn
- 2003-07-18 AU AU2003259169A patent/AU2003259169A1/en not_active Abandoned
- 2003-07-18 PL PL03375388A patent/PL375388A1/en not_active Application Discontinuation
- 2003-07-18 NZ NZ537203A patent/NZ537203A/en unknown
- 2003-07-18 BR BR0313420-2A patent/BR0313420A/en not_active IP Right Cessation
- 2003-07-18 RU RU2005105337/04A patent/RU2005105337A/en not_active Application Discontinuation
- 2003-07-18 WO PCT/US2003/022587 patent/WO2004014893A2/en active Application Filing
- 2003-07-18 JP JP2004527622A patent/JP2005536532A/en not_active Withdrawn
-
2005
- 2005-01-25 MA MA28065A patent/MA27467A1/en unknown
- 2005-01-31 ZA ZA200500877A patent/ZA200500877B/en unknown
- 2005-02-28 NO NO20051082A patent/NO20051082L/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0342675A2 (en) * | 1988-05-19 | 1989-11-23 | Chugai Seiyaku Kabushiki Kaisha | Novel quinolonecarboxylic acid derivatives |
WO1999014214A1 (en) * | 1997-09-15 | 1999-03-25 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
US20020049192A1 (en) * | 1997-09-15 | 2002-04-25 | The Procter & Gamble Company | Antimicrobial quinolones, their compositions and uses |
WO2002048138A1 (en) * | 2000-12-14 | 2002-06-20 | The Procter & Gamble Company | Antimicrobial quinolones |
Non-Patent Citations (1)
Title |
---|
SUTO M J ET AL: "FLUOROQUINOLONES: RELATIONSHIPS BETWEEN STRUCTURAL VARIATIONS, MAMMALIAN CELL CYTOTOXICITY, AND NATIMICROBIAL ACTIVITY" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 35, no. 25, 1992, pages 4745-4750, XP001094135 ISSN: 0022-2623 * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7507727B2 (en) | 2003-04-07 | 2009-03-24 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs and methods of using thereof |
US7163948B2 (en) | 2003-04-07 | 2007-01-16 | Cylene Pharmaceuticals, Inc. | Heterocyclic substituted 1,4-dihydri-4ox9-1,8-naphthyridine analogs |
US7141565B1 (en) | 2003-04-07 | 2006-11-28 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs |
US7326702B2 (en) | 2003-04-07 | 2008-02-05 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs |
US7354916B2 (en) | 2003-04-07 | 2008-04-08 | Cylene Pharmaceuticals | Substituted quinobenzoxazine analogs |
US7381720B2 (en) | 2003-04-07 | 2008-06-03 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs |
US7612063B2 (en) | 2003-04-07 | 2009-11-03 | Cylene Pharmaceuticals, Inc. | Substituted quinobenzoxazine analogs |
US7816406B2 (en) | 2004-09-17 | 2010-10-19 | Cylene Pharmaceuticals, Inc. | Quinolone analogs |
US7652134B2 (en) | 2004-09-17 | 2010-01-26 | Cylene Pharmaceuticals, Inc. | Methods for converting quinolone esters into quinolone amides |
US7528264B2 (en) | 2006-03-28 | 2009-05-05 | The Procter & Gamble Company | Hydride reduction process for preparing quinolone intermediates |
US7456279B2 (en) | 2006-03-28 | 2008-11-25 | The Procter & Gamble Company | Coupling process for preparing quinolone intermediates |
WO2007110836A1 (en) * | 2006-03-28 | 2007-10-04 | The Procter & Gamble Company | A hydride reduction process for preparing quinolone intermediates |
KR101030202B1 (en) * | 2006-03-28 | 2011-04-22 | 워너 칠콧 컴퍼니 엘엘씨 | A hydride reduction process for preparing quinolone intermediates |
US8039485B2 (en) | 2006-03-28 | 2011-10-18 | Warner Chilcott Company, Llc | Malate salts, and polymorphs of (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid |
US7723355B2 (en) * | 2006-11-20 | 2010-05-25 | Bristol-Myers Squibb Company | 7,8-dihydro-1,6-naphthyridin-5(6H)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase IV and methods |
WO2009046383A1 (en) * | 2007-10-05 | 2009-04-09 | Cylene Pharmaceuticals, Inc. | Quinolone analogs and methods related thereto |
US8853234B2 (en) | 2007-10-05 | 2014-10-07 | Senhwa Biosciences, Inc. | Quinolone analogs and methods related thereto |
US7928100B2 (en) | 2007-10-05 | 2011-04-19 | Cylene Pharmaceuticals, Inc. | Quinolone analogs and methods related thereto |
EP2376477A2 (en) * | 2008-12-15 | 2011-10-19 | Taigen Biotechnology Co., Ltd. | Stereoselective synthesis of piperidine derivatives |
JP2012512172A (en) * | 2008-12-15 | 2012-05-31 | タイゲン バイオテクノロジー カンパニー,リミテッド | Stereoselective synthesis of piperidine derivatives. |
EP2376477A4 (en) * | 2008-12-15 | 2012-08-08 | Taigen Biotechnology Co Ltd | Stereoselective synthesis of piperidine derivatives |
AU2009333391B2 (en) * | 2008-12-15 | 2013-05-02 | Taigen Biotechnology Co., Ltd. | Stereoselective synthesis of piperidine derivatives |
WO2010077798A2 (en) | 2008-12-15 | 2010-07-08 | Taigen Biotechnology Co., Ltd. | Stereoselective synthesis of piperidine derivatives |
US10857156B2 (en) | 2015-11-20 | 2020-12-08 | Senhwa Biosciences, Inc. | Combination therapy of tetracyclic quinolone analogs for treating cancer |
US11229654B2 (en) | 2015-11-20 | 2022-01-25 | Senhwa Biosciences, Inc. | Combination therapy of tetracyclic quinolone analogs for treating cancer |
US9957282B2 (en) | 2015-12-14 | 2018-05-01 | Senhwa Biosciences, Inc. | Crystalline forms of quinolone analogs and their salts |
US11524012B1 (en) | 2018-02-15 | 2022-12-13 | Senhwa Biosciences, Inc. | Quinolone analogs and their salts, compositions, and method for their use |
WO2019206798A1 (en) * | 2018-04-25 | 2019-10-31 | Bayer Animal Health Gmbh | Process for the hydrolysis of quinolone carboxylic esters |
US11332444B2 (en) | 2018-04-25 | 2022-05-17 | Bayer Animal Health Gmbh | Method for the hydrolysis of quinolonecarboxylic esters |
Also Published As
Publication number | Publication date |
---|---|
MXPA05001180A (en) | 2005-05-16 |
PL375388A1 (en) | 2005-11-28 |
MA27467A1 (en) | 2005-08-01 |
AU2003259169A1 (en) | 2004-02-25 |
CA2493146A1 (en) | 2004-02-19 |
NO20051082L (en) | 2005-04-29 |
JP2005536532A (en) | 2005-12-02 |
EP1532137A2 (en) | 2005-05-25 |
BR0313420A (en) | 2005-06-28 |
RU2005105337A (en) | 2006-01-20 |
US20040038975A1 (en) | 2004-02-26 |
CN1671690A (en) | 2005-09-21 |
US6900224B2 (en) | 2005-05-31 |
WO2004014893A3 (en) | 2004-04-08 |
IL166041A0 (en) | 2006-01-15 |
NZ537203A (en) | 2007-02-23 |
KR20050026074A (en) | 2005-03-14 |
ZA200500877B (en) | 2006-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002230891B2 (en) | Antimicrobial quinolones | |
EP1532137A2 (en) | Antimicrobial aza-bicyclic derivates, their compositions and uses | |
US7868021B2 (en) | Antimicrobial quinolones, their compositions and uses | |
AU2002230891A1 (en) | Antimicrobial quinolones | |
US6387928B1 (en) | Antimicrobial quinolones, their compositions and uses | |
AU2002230893B2 (en) | Antimicrobial 2-pyridones, their compositions and uses | |
AU2002230893A1 (en) | Antimicrobial 2-pyridones, their compositions and uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003784784 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 537203 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4175/DELNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200500003 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-500109 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2493146 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004527622 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 05006803 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/001180 Country of ref document: MX Ref document number: 2003259169 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/00877 Country of ref document: ZA Ref document number: 375388 Country of ref document: PL Ref document number: 20038183137 Country of ref document: CN Ref document number: 1020057001728 Country of ref document: KR Ref document number: 200500877 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2005105337 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057001728 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003784784 Country of ref document: EP |